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Abstract 
Several of the newly developed drug molecules experience poor biopharmaceutical 
behavior, which hinders their effective delivery at the proper site of action. Several 
strategies are currently being employed in order to overcome this obstacle, namely by 
associating the drug molecules with suitable carriers. Mesoporous silicon-based materials 
have emerged as promising drug carriers due to their ability to improve the dissolution 
behavior of several poorly water-soluble drugs compounds confined within their pores. 
The  aim  of  this  thesis  was  to  investigate  the  biocompatibility,  cellular  interaction,  drug  
release and biodistribution of different types of surface treated porous silicon (PSi) micro- 
and nanoparticles, such as thermally oxidized (TOPSi) and thermally hydrocarbonized 
(THCPSi). 
 
Studies conducted on TOPSi and THCPSi particles have showed that nanoparticles have a 
higher degree of biocompatibility than microparticles in RAW 264.7 macrophages and 
Caco-2 cells. The TOPSi and THCPSi nanoparticles improved the permeability of Caco-2 
cell monolayers for the drug compounds indomethacin and griseofulvin. However, both 
types of surface treated particles were found not to permeate across the differentiated 
Caco-2 cell monolayers even after 24 h incubations, but were readily internalized by RAW 
264.7 macrophages. In addition, the degradation of the nanoparticles showed its potential 
to fast clearance in the body. Radiolabeled nanoparticles administered intravenously in 
rats were found to be quickly translocated to liver and spleen, without apparent toxic 
effects.  These  results  constituted  the  first  quantitative  analysis  of  the  behavior  of  orally  
administered THCPSi nanoparticles compared with other delivery routes in rats. 
 
The self-assemble of a hydrophobin class II (HFBII) protein at the surface of THCPSi 
particles endowed the particles with greater biocompatibility in different cell lines (AGS, 
Caco-2 and HT-29) and was also found to reverse their hydrophobicity and protected a 
drug loaded within its pores against premature release at low pH (1.2), while enabling 
subsequent drug release as the pH was increased. The permeability of the drug compound 
across a differentiated Caco-2 monolayer was undisturbed by the presence of the HFBII-
coating and was found to be higher for the coated and uncoated THCPSi particles than for 
the bulk drug. The protein-coated particles were also found to increase cell association in 
vitro and to promote gastroretentivity in vivo. These results highlight the potential of 
HFBII-coating for PSi-based drug carriers in improving their hydrophilicity, 
biocompatibility and pH responsiveness in drug delivery applications. 
 
In conclusion, mesoporous silicon particles have been shown to be a versatile platform for 
improving the dissolution behavior of poorly water-soluble drugs with high 
biocompatibility and easy surface modification. The results of this study also provide 
information regarding the biofunctionalization of the THCPSi particles with a fungal 
protein, leading to an improvement in their biocompatibility and endowing them with pH 
responsive and mucoadhesive properties. 
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1 Introduction 
The recognition that unfavorable physicochemical properties of many drug compounds 
affect their bioavailability and consequently the efficacy of the treatment, has led to intense 
research in the field of drug delivery. It has been reported that nearly 50% of all the newly 
developed lead optimization compounds entering the development pipeline fail because of 
non-optimal physicochemical and biopharmaceutical properties (Singh et al., 2011). A 
substantial factor that prevents the development of such substances is the limited 
dissolution rate. There are currently several strategies employed in order to increase the 
dissolution behavior of poorly water-soluble drugs, such as oral lipid-based (Hauss, 2007), 
amorphous formulations (Kawakami, 2009), or delivery systems, such as cyclodextrins 
(Loftsson et al., 2007; Loftsson and Brewster, 2010).  
 
In order to overcome some of the barriers of drug absorption in the body, the study of drug 
delivery systems has been actively pursued in the last decades (Hoffman, 2008). The idea 
of a drug carrier, which would deliver the drug compounds at the appropriate site of action 
and at the same time maintaining the physiological milieu undisturbed has been long 
sought after and holds tremendous economical potential. The drug delivery market is one 
of the most profitable areas within the pharmaceutical industry with about $94 billion value 
and a 10% annual increase worldwide in 2010 (GBI-Research, 2010). However, the 
material properties of drug carriers very often also affect the drug’s fate, drug release rate, 
toxicity of the drug carriers, as well as the drug carrier’s biocompatibility and safety (Karp 
and Langer, 2007; Kohane and Langer, 2010).  
 
In addition to the safety and biocompatibility, drug delivery systems should also 
encompass high payloads, protect the drug against degradation, allow the release of an 
effective drug concentration at the appropriate site of action and allow some degree of 
control over the drug’s pharmacokinetic distribution profile (Peer et al., 2007). Therefore, 
the materials used in biomedical applications should be suitably designed in order to 
achieve a specific biological response, which can derive from the control exerted over their 
mechanical properties, surface microstructure, texture, porosity and compartmentalization 
(Mitragotri and Lahann, 2009).  
 
Along with the material properties of the carriers, their physical dimensions and shape were 
also found to greatly impact their drug delivering properties. Materials at nanoscale have 
been found to encompass very advantageous mechanical, electrical, chemical and optical 
features, which are currently being exploited for numerous applications (West and Halas, 
2003; Chopra et al., 2007). In the material sciences field, nanomaterials are engineered 
structures with at least one dimension bellow 100 nanometers (nm) (Nel et al., 2006), 
although in the pharmaceutical science field this definition has been used rather loosely and 
might  include  structures  up  to  1  µm  in  either  dimension.  By  taking  advantage  of  the  
valuable properties of nanoscale delivery systems, such as increased surface area, improved 
solubility of hydrophobic drugs, possibility to encapsulate and protect drugs from 
degradation and reduced immunogenic potential and toxicological effect, further 
developments and innovative drug delivery systems can still be engineered (Couvreur and 
Vauthier, 2006).  
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However, these nano-sized drug delivery systems can also elicit undesired biological or 
toxicological effects (Oberdorster, 2010). This can be related to their own size, shape and 
surface chemistry (Jiang et al., 2008; Mitragotri and Lahann, 2009; Yoo et al., 2010; Yoo 
et al., 2011), as well as other hazards resulting from the fabrication process. Nano-
engineered structures have been shown to display different stability, behavior in the 
biological microenvironment, and cellular distribution according to their dimensions, 
morphology and chemical constitution. Safety and biocompatibility of these engineered 
structures is, therefore, a requirement both in manufacture and, more importantly, when in 
vivo exposure or administration is concerned. Therefore, in order for a drug delivery carrier 
to be deemed suitable, it should prove its efficacy along with its safety when administered 
in the body.  
 
Mesoporous materials, are materials containing pores with diameters between 2 and 50 nm 
(Rouquerol et al., 1994) and meet some of the aforementioned requirements for drug 
delivery systems. Their large surface area (> 700 m2/g) and large pore volume (> 0.9 
cm3/g) can enable their use as drug reservoirs for storing hydrophobic molecules, while 
allowing an easy tailoring of the pore size (Santos et al., 2011). The drug loading properties 
and cellular interaction of mesoporous materials can be further modulated by tuning their 
shape, size, pore or surface functionalization. In addition, mesoporous materials have a 
well-defined structure and surface, are relatively inexpensive, thermally stable and 
chemically inert (Salonen et al., 2008). 
 
Among several mesoporous materials that can be found in the literature, porous silicon 
(PSi) has attracted significant attention due to its interesting properties that enable it to be 
employed in several biomedical applications (He et al., 2010), such as drug delivery 
carriers or implantable devices (Zangooie et al., 1998; Canham et al., 1999; Desai et al., 
1999; Stewart and Buriak, 2000; Anglin et al., 2008; Salonen et al., 2008). In addition to its 
drug delivery properties, PSi was also found to be biocompatible (Canham, 1995) and 
biodegradable (Park et al., 2009). The biodegradation of PSi can even be modulated to 
some extent by controlling overall porosity, pore size, shape, surface and bulk properties 
(Canham, 1997). The drug loading degree of PSi was also shown to be affected by several 
properties of the material, such as hydrophilicity/hydrophobicity, pore size, surface 
chemistry, loaded compound (charge, chemical nature, shape and molecular size), and drug 
loading method (Salonen et al., 2005; Limnell et al., 2007; Prestidge et  al., 2008). The 
fabrication method even allows the PSi to remain stable under the stringent conditions of 
the stomach and gastrointestinal (GI) lumen, while maintaining its advantageous drug 
delivering properties (Salonen et  al., 2008). The challenges of engineering PSi carriers, 
which can successfully deliver their drug payloads at the site of action while maintaining a 
tolerable toxic profile, are still partially unmet. A thorough understanding of the biological 
phenomena surrounding the interaction of PSi materials with the physiological 
environment, in vitro/vivo, is therefore, required in order for this material to fulfill its 
promise as a suitable drug delivery system. 
 
The objectives of this dissertation were to thoroughly characterize PSi particles of different 
sizes and surface chemistries by several well-established analytical techniques and to 
assess the biocompatibility and biodistribution of plain and protein-coated PSi particles, 
along with the corroboration of its potential to increase drug dissolution. For that purpose 
the following approaches were conducted: (1) visual characterization employing several 
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microscopy techniques; (2) assessment of cellular viability, reactive oxygen species (ROS) 
and inflammatory response; (3) loading with poor water-soluble drugs and assess their 
dissolution and permeation behaviour; (4) evaluation of biocompatibility and cellular 
association of the protein-coated particles; and finally (5) biodistribution studies in rats. 
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2 Review of the literature 
2.1 Solubility of drug compounds 
The goal of pharmacological therapy is to elicit a response from drug administration which 
can reverse a pathological condition (Chan and Holford, 2001). Such response is dependent 
on the availability of the active drug at the receptor site, which in turn is influenced by the 
plasma drug concentrations (Smolen, 1978). The water solubility of a compound is 
therefore  a  crucial  parameter  for  the  drug  to  be  effective  at  the  target  site.  By definition,  
and according to the International Union of Pure and Applied Chemistry (IUPAC), “the 
analytical  composition  of  a  saturated  solution,  expressed  in  terms  of  the  proportion  of  a  
designated solute in a designated solvent, is the solubility of that solute”. The solubility 
may be expressed as a concentration, molality, mole fraction, mole ratio, etc. (McNaught 
and Wilkinson, 1997). Chemical entities can be therefore divided according to their 
solubility, into highly or poorly soluble. In the U.S. and Eur. Pharmacopoeias, the 
solubility is stated by the descriptive terms shown in Table 1. 
Table 1 Descriptive terms for the solubility used in the pharmacopoeias (USP, 2009; Ph. Eur., 
2009). 
Term Parts of solvent required for 1 part of solute 
Very soluble Less than 1 
Freely soluble From 1 to 10 
Soluble From 10 to 30 
Sparingly soluble From 30 to 100 
Slightly soluble From 100 to 1000 
Very slightly soluble From 1000 to 10 000 
Practically insoluble, or insoluble Greater than or equal to 10 000 
 
Furthermore, in order for a compound to be effectively absorbed in the body, orally-
administered drugs need also to be dissolved at the site of absorption in the GI tract 
(Avdeef, 2001).  Then, the compounds are required to transverse several lipid barriers in 
order to find their way into the systemic circulation. The ability of a compound to diffuse 
across lipid membranes is termed permeation and is directly correlated with the drug’s 
lipophilicity. It is therefore required that besides possessing some degree of aqueous 
solubility, the drug displays adequate permeability. Highly-permeable drugs are generally 
those with an extent of absorption greater than or equal to 90% and are not generally 
associated with any documented instability in the GI tract (Martinez and Amidon, 2002). 
However, even if the drug has reasonable membrane permeation properties, the rate-
limiting process of absorption is still the drug dissolution step (Singh et al., 2011).  
 
The pharmaceutical research of new chemical entities has reached a stage where poorly 
water-soluble drug compounds (< 1 ?g/ml) are a considerable bottleneck in the drug 
discovery pipeline (Lipinski et al., 1997; Lipinski, 2000). In order to overcome this 
difficulty and even to reinstate the research of molecules that exhibited adequate efficacy, 
but were excluded by their unfavorable physicochemical properties, several strategies can 
be employed. One strategy to improve the drug’s bioavailability, as well as its 
pharmacological and therapeutic properties with reduced collateral effects, is to associate 
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the compounds with another entity which serves as a carrier agent. This approach for the 
delivery of drug compounds can be termed carrier-mediated drug delivery, which allows 
poorly water-soluble drugs to be confined within the carrier. In this case, the drug can be 
delivered at the site of absorption and also targeted to a specific site while being sheltered 
from any unwarranted degradation (Singh et al., 2011). A carrier or drug delivery agent can 
be basically described as a formulation that controls the rate and period of drug delivery 
and can target specific areas of the body (Poznansky and Juliano, 1984). 
 
Mesoporous materials, i.e. materials which have pores with dimensions between 2 and 50 
nm, have been found to be excellent candidates for drug delivery systems due to their 
unique features, such as a high pore volume, capable of hosting the required amount of 
compounds; high surface area, which implies high potential for drug adsorption; and 
tunable pore size with a narrow distribution, which enables a reproducible loading and 
release of the compounds (Vallet-Regí et al., 2007). When the drug molecules are loaded in 
the microfabricated porous materials, many of the abovementioned dissolution-related 
problems can be overcome. The crystalline drug is restricted by the confined space of the 
pores (usually not much larger than the drug molecule), retaining the drug in its amorphous 
(non-crystalline) disordered form (Salonen et al., 2005). Consequently, an increase in 
solubility and dissolution rate of the drugs is achieved as a result of the low lattice energy 
(high Gibbs free energy) of the amorphous state. The confinement of the compounds within 
the pores of mesoporous materials allows the attainment of high local drug concentrations 
and even drug supersaturation, thus increasing the net absorption and respective permeation 
across biological barriers (Kaukonen et al., 2007; Brouwers et al.,  2009).  One  of  the  
structures that has shown great promise in the confining and release of poorly water-
soluble drug compounds was PSi which has been also actively investigated for biomedical 
applications (Salonen et al., 2008). 
2.2 Porous silicon (PSi) 
Although silicon (Si) does not occur in nature in free form, in its combined form it 
accounts for nearly 25% of the earth's crust (Yaroshevsky, 2006). Si-based compounds are 
distinctive materials both in terms of their chemistry and in their numerous useful 
applications. Si in combination with organic compounds provides unique properties that 
function over a wide range of temperature, making these products less temperature 
sensitive than most organic surfactants. These properties can be credited to the strength and 
flexibility of the Si-O bond, its partial ionic character and the low interactive forces 
between the non-polar methyl groups, characteristics that are directly related to the 
comparatively long Si-O and Si-C bonds. The length of the Si-O and Si-C bonds also 
allows an unusual freedom of rotation, which enables the molecules to adopt the lowest 
energy configuration at interfaces, providing a surface tension that is substantially lower 
than that of organic polymers (O'Lenick, 2009).  
 
One interesting form of Si is PSi, which incorporates varying porosity in its structure, 
rendering a large surface-to-volume ratio of above 500 m2/cm3. The discovery of PSi was 
made accidentally by Arthur Uhlir Jr. and Ingeborg Uhlir in 1956 at Bell Labs (Uhlir, 
1956). Their initial purpose was to develop a technique for polishing and shaping the 
surfaces of Si and germanium. However, they found that under several conditions, a rough 
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product in the form of a thick black, red or brown film was formed on the surface of the 
material. At the time, these findings were only referred as a scientific oddity and briefly 
mentioned in their technical notes, without noting their porous structure. It was Watanabe 
and co-workers who first reported their porous nature (Watanabe and Sakai, 1971), but it 
was not until the late 1980s that Leigh Canham and simultaneously Lehmann and Gösele 
speculated that the diaphanous Si filaments generated when the pores became large and 
numerous enough to interconnect, might exhibit quantum confinement effects (Canham, 
1990; Lehmann and Gosele, 1991). In addition, it was discovered that the Si wafers could 
emit visible light at room temperature if subjected to electrochemical and chemical 
dissolution.  These  findings  led  to  a  substantial  amount  of  research  focused  on  the  
development of Si-based optoelectronic switches, displays and lasers (Soref, 1993; Canham 
et al., 1996). However, due to the material’s mechanical and chemical instability and its 
low electroluminescence efficiency, most of the interest in that field subsequently faded. 
Nonetheless, due to its other remarkable characteristics, such as large surface area-to-
volume ratio, the ability to fine tune its pore size, its surface chemistry and the established 
microfabrication technologies, PSi application were further investigated in several other 
fields such as Si membranes (Chu et  al., 1999) and drug delivery carriers (Anglin et al., 
2008; Salonen et al., 2008; Serda et al., 2011).  
2.2.1 Manufacture and properties  
There have been several methods reported in the literature for the fabrication of PSi 
materials. The most frequent method is electrochemical anodization of monocrystalline 
silicon wafers in aqueous ethanolic hydrofluoric acid (HF) electrolytes (Salonen and Lehto, 
2008). In its simpler setup, the Si wafer acts as anode while a platinum (Pt) plate serves as 
a cathode, when both are immersed in the HF-ethanolic solution and current is applied 
(Figure 1). The almost exclusive use of Pt as a cathode material is due to the fact that Pt is 
practically the only conductive material which can repeatedly withstand the stringent 
cathodic  conditions.  The  cell  in  which  the  anodization  takes  place  must  also  be  made  of  
HF-resistant material in order to endure the whole etching process. The core properties of 
the  obtained  PSi,  such  as  porosity,  pore  layer  thickness,  pore  size  and  shape  are  all  
determined by the fabrication conditions (Salonen et al., 2000). These conditions include 
current density, wafer type and resistivity, HF concentration, chemical composition of the 
electrolytes, crystallographic orientation, temperature, time, electrolyte stirring, 
illumination intensity and wavelength. All these conditions are very difficult to control 
completely during the fabrication process. However, as the majority of these parameters are 
somehow related to each other and can be kept constant, a satisfactory degree of 
reproducibility can be achieved. 
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Figure 1 Schematic representation of a simple etching setup for PSi fabrication. Pt is the 
cathode and the Si wafer the anode in a HF-ethanolic solution. Modified from Salonen 
and Lehto, 2008. Copyright © (2008) Elsevier. Reprinted with permission. 
The doping levels of the initial Si wafer were also found to influence the pore morphology 
of the PSi (Zhang, 2001). Based on the doping levels of the substrate, the Si wafers can be 
divided into n, n+, p and p+-type, where n- and n+-type Si is usually doped with antimony 
or phosphorous and p- and p+-type Si with boron. With p type, the pore size increases with 
dopant concentration, whereas with n-type, the low dopant concentration generates usually 
macropores, while increasing to higher dopant levels causes mesopores to form (Lehmann 
et al., 2000). The n-type Si usually yields pores with larger diameters than the p-type, and 
the  pores  seem  to  form  straighter  cylindrical  structures  in  the  <100>  direction  (Levy-
Clement, 1995).  
 
The HF concentration in the electrolyte can also modulate the pore morphology. By 
decreasing the HF concentration, the pore diameter increases in the Si substrate 
(Halimaoui, 1997; Zhang, 2001) and pores become straighter and smoother. The use of 
electrolyte diluting agents other than water (e.g. ethanol) has also been found to lead to the 
formation of smoother and larger pores. The pore shapes are frequently observed to be 
cylindrical (or spherical), but rectangular pores have also been reported, at least in n-type 
PSi (Smith and Collins, 1992; Cullis et al., 1997).  
 
Despite the fact that electrochemical anodization is the method most commonly used to 
fabricate PSi, the stain etching method can also be employed. This method resembles the 
electrochemical etching, but is based completely on chemical reactions, without the use of 
any additional current (Archer, 1960; Fathauer et  al., 1992; Shih et al., 1992; Kolasinski, 
2005). In stain etching, the hole generation is also required, but for this purpose an oxidant 
is added in the HF electrolyte, usually HNO3 (Liu et  al., 1994; Parbukov et al., 2001; 
Guerrero-Lemus et al., 2003). The rate of PSi layer growth is directly proportional to the 
concentration of HNO3, irrespective of the substrate resistivity. In aqueous HF and HNO3 
solutions, the cathodic reactions produce NO, because it serves as the hole-injector, 
enabling the Si dissolution. One disadvantage of stain etching is the heterogeneous etching 
profile, due to the fact that both the cathodic and anodic sites are randomly, but constantly, 
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present on the Si surface during etching. The other disadvantage of stain etching is the 
limited thickness of the PSi layer formed, and also the poorer reproducibility compared 
with the PSi samples produced by anodization. However, recent reports concerning the 
stain etching method have shown promising results regarding a more controlled and thicker 
stain etched PSi layers using non-conventional etching solutions (Kolasinski et al., 2010). 
Another method of PSi fabrication is by photosynthesis, where visible-light irradiation 
alongside a HF electrolyte was used to produce PSi without the need of any electrodes for 
anodization (Noguchi and Suemune, 1993). A method relying on ball milling combined 
with pressing sintering procedures has also been described in the literature for the 
fabrication of PSi (Jakubowicz et al., 2007). In addition, a method relying on solid flame 
synthesis,  where  PSi  is  formed  as  Si  dioxide  (SiO2) reacts with Mg in a combustion 
chamber followed by an acid treatment, has also been reported (Won et al., 2009). 
2.2.2 Surface chemistry and stabilization 
Following anodization, the PSi surface is hydrogen terminated (Si-Hx). These bonds can be 
hybrids Si-H, Si-H2 and  Si-H3 and render the Si surface prone to oxidation even in dry 
ambient air (Burrows et al., 1988; Canham et al., 1991; Salonen et al., 2008; Salonen and 
Lehto, 2008). Already in the 1960s, Beckmann found out that PSi films were clearly aged 
when they were stored at ambient air for an extended period (Beckmann, 1965). This was 
due not only to the native oxidation of PSi, but also due to some other reactions resulting 
from the storage conditions (Loni et al., 1997). The rate and extent of oxidation from the 
hydrophobic hydrogen termination to hydrophilic oxidized surface takes a few months at 
room temperature. Complete native oxidation takes much longer time, depending on the 
storage conditions. In addition, there are also some impurities present in the PSi, which are 
commonly detected after the fabrication procedure, such as fluorine, oxygen and trace 
amounts of hydrocarbons (Grosman and Ortega, 1997). For most applications, a non-
reactive and stable surface is crucial, and the unstable hydrogen termination of the freshly 
etched PSi has to be replaced. By converting the reactive groups into a more stable 
oxidized, hydrosilylated or (hydro) carbonized form, the PSi surface can be modified even 
further in terms of hydrophilicity and resistance to oxidation (Table 2). 
Table 2 Surface chemistries, typical Si bonding, hydrophilicity and resistance to oxidation of 
as-anodized and several surface-treated PSi. 
2.2.2.1 Thermal oxidation  
The stabilization of the anodized Si surfaces by thermal oxidation is one of the more 
straightforward ways to oxidize Si surfaces; the product of this treatment is called 
thermally oxidized PSi (TOPSi) (Petrova-Koch et al., 1992; Salonen et al., 1997). The 
Surface chemistry Bonds Hydrophilicity Resistance to oxidation 
As-anodized Si-H - - 
Thermally oxidized Si-O ++ + 
Thermally carbonized Si-C + ++ 
Thermally hydrocarbonized Si-C-H - +++ 
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modification of the PSi surface chemistry via thermal oxidation has been extensively 
studied and has demonstrated the conversion of the native SiySiHx surface  to  OySiH, 
OySiOH and SiOSi (Kumar et al., 1993; Takazawa et al., 1994; Mawhinney et al., 1997). 
The thermal oxidation starts to occur at a threshold temperature near 250 ºC where there is 
the first evidence for loss of hydrogen from the Si surface, and where the Si dangling bond 
sites produced are able to chemisorb O2 dissociatively, leading to the first stage of surface 
oxidation. Oxidation leads to O insertion into Si-Si back-bonds, producing -OySiHx species. 
Oxidation also leads to the formation of surface Si-OH species as a result of the O insertion 
into Si-H bonds. The subsequent formation of Si-O-Si modes is originated from oxidation 
of the PSi surfaces (Mawhinney et al., 1997). This method, depending on the treatment 
temperature, forms a thin layer of SiO2 on the surface of PSi, resulting in a slight decrease 
in pore diameter. In addition, the oxidation changes the surface from hydrophobic to 
hydrophilic (Salonen et al., 2008). Besides thermal oxidation, anodic, photo and chemical 
oxidation can also be employed on the Si surface (Canham, 1990; Li et al., 1993; 
Halimaoui, 1997). The fact that the thermal oxidation changes the silicon surface from 
hydrophobic to hydrophilic renders the material more compatible with the body´s aqueous 
environment, which is crucial in order to minimize inflammation and enhance 
biocompatibility (Hezi-Yamit et al., 2009). 
2.2.2.2 Thermal hydrocarbonization 
It is also possible to obtain a hydrocarbon terminated surface using thermal decomposition 
of acetylene. This method allows the surface treatment to be conducted at a lower 
temperature, since there is a threshold temperature which changes the thermal 
functionalization of PSi into carbonization. The threshold temperature, however, allows a 
continuous flow of acetylene to be used without any graphitization problems. At treatment 
temperatures below 700 °C, the hydrogen atoms remain on the PSi surface making it 
hydrophobic (Si-C-H bonds; thermally hydrocarbonized PSi, THCPSi). (Salonen et al., 
2004). The thermal carbonization with acetylene changes surface structure, whereas the 
silylation  reactions  change  the  the  surface  Si-H  chemistry.  The  use  of  the  small  gaseous  
molecule acetylene in the process has some advantages, such as faster and better diffusion 
in the pores, which improves the efficiency of surface coverage. This surface treatment has 
some important advantages compared with the carbonized surface, e.g. it is still 
hydrophobic; the treated layer is thin; and the gas adsorption properties are different from 
those found in the thermal carbonized (TC) PSi surface (Salonen et al., 2004). 
Functionalization of THCPSi by radical coupling of sebacic acid has been also reported, as 
well as their capability to further modify the surface using standard bioconjugate chemistry 
methods (Sciacca et al., 2010). The authors stated that the material was obtained at 500 °C, 
thus confirming the THC surface. The surface was stable and comparable to a non-
functional thermal oxide, but superior to the widely used carboxyl-terminated surface 
prepared by the thermal hydrosilylation route.  
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2.2.2.3 Other surface treatments 
Besides the aforementioned treatments to the PSi surfaces, which modulate the surface in 
terms of its hydrophilicity and resistance to oxidation, other treatments which allow further 
functionalization of the Si surface have also been reported. The thermal carbonization was 
one of the first methods employed to stabilize the silicon surface, involving chemical 
derivations of the PSi surface with organic compounds and formation of Si-C bonds (Dubin 
et al., 1995; Linford et al., 1995; Sailor and Song, 1998). When the temperature is above 
700 °C the formed surface is hydrogen free and more hydrophilic than the material 
produced at lower temperatures Early works in this area focused on single-crystal reactions 
that involved heating, which in turn can potentially damage the fragile nanoscale 
architecture of the PSi, and the use of likely contaminating late transition metals or high 
vacuum conditions (Buriak, 1999). Subsequently, several groups have also investigated the 
formation of Si-C bonds on porous silicon at room temperature using one- or two-step wet 
chemical techniques (Buriak and Allen, 1998; Buriak and Stewart, 1998; Kim and Laibinis, 
1998). Stability studies of differently stabilized PSi samples have shown that the TCPSi is 
an even more efficient stabilizing method than the thermal oxidation (Björkqvist et al., 
2004). A hydrosilylation approach towards formation of Si-C bonds on PSi, involving 
alkynes and alkenes, which yields surface bound vinyl and alkyl groups respectively has 
also been described (Zazzera et al., 1997). The surfaces prepared through this route are 
remarkably stable to boiling alkali solutions, indicating that the degree of coverage is 
sufficient to fully protect the exposed surface. In contrast, the Si-H terminated PSi 
dissolves in minutes under these conditions (Buriak and Allen, 1998). Other treatments also 
included hydrosilylation of undecylenic acid (Boukherroub et al., 2002; Wu et al., 2011), 
in which the free carboxyl groups of undecylenic acid are covalently bonded on the surface 
and can be used to further surface functionalization; and the 3-aminopropyltriethoxysilane 
(APTES), where the molecule has been used as organometallic precursor (Arroyo-
Hernandez et al., 2006). 
 
2.2.3 Biomedical applications 
The discovery that PSi behaved as a bioactive material (Canham, 1995) instigated the 
scientific community in further pursuing PSi studies for biomedical applications. Reports 
on in vitro studies covering calcification (Canham, 1995; Canham and Reeves, 1996; 
Canham et al., 1996; Rosengren et al., 2000; Coffer et al., 2003; Seregin and Coffer, 
2006), cell adhesion and culturing (Bayliss et al., 2000; Chin et al., 2001; Sapelkin et al., 
2006), neural networks (Sapelkin et al., 2006), protein adsorption (Collins et al., 2002; 
Karlsson et al., 2003; Karlsson et al., 2004; Prestidge et al., 2007; Prestidge et al., 2008), 
and biodegradability studies (Canham et al., 1999; Canham, 2000; Anderson et al., 2003) 
have been published since. Also, some initial in vivo assessments of tissue compatibility 
have been carried out (Bowditch et al., 1999; Rosengren et al., 2000). Due to its large 
specific surface area and easily functionalized surface chemistry, PSi-based materials were 
further investigated in areas such as implantable devices (Santini et  al., 1999; Sharma et 
al., 2006), biomolecular screening (Nijdam et al., 2007; Nijdam et al., 2009) and optical 
biosensing (Lehmann and Gösele, 1991; Palestino et al., 2008). The possibility to fabricate 
optical multilayer structures not only enabled the use of PSi in optical sensor applications, 
but also in detecting changes in electrical, optical and photoluminescence properties 
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(Salonen and Lehto, 2008). The development of PSi materials for brachytherapy and for 
implantable drug delivery for the treatment of chronic eye diseases has already been given 
approval by the Food and Drug Administration (FDA). The PSi-based product BrachysilTM 
of pSivida Ltd., the leading company in the biomedical applications of PSi, has already 
advanced to Phase II clinical trials for inoperable primary liver and pancreatic cancer 
(Zhang et al., 2005; Goh et al., 2007).  
2.2.3.1 Biocompatibility and biodegradation 
Biofunctionalization of the PSi surface is a crucial step considering potential in vivo 
applications. The surface chemistry should be designed in order to obtain the desired 
effects, and should be stable enough for the intended purpose, and yet displaying 
bioactivity. The first report on PSi biocompatibility came from Leigh Canham which 
investigated the growth of hydroxyapatite on top of the PSi in simulated body fluids 
(Canham, 1995). Subsequent studies showed several other remarkable properties of PSi 
such as high controllability, bio-inertness, bioactiveness, and resorbability (Canham, 2000; 
Arroyo-Hernández et al., 2003). In addition to the biocompatibility, PSi biodegradation can 
also be controlled by the overall porosity, pore size, shape, surface and bulk properties 
(Canham, 1997; Decuzzi et al., 2009), which in turn can be controlled by the choice of the 
material fabrication parameters (Anglin et al., 2008; Tasciotti et al., 2008). For instance, 
PSi with a porosity >70% dissolves in all the simulated body fluids (except gastric fluids), 
whereas PSi with a porosity <70% is bioactive and slowly biodegradable (Salonen et al., 
2008). Furthermore, macroporous Si is a rather bioinert material, as its bioactivity has also 
been showed to be dependent on the pore size (Canham et al., 1996).  
 
The  fact  that  PSi  degrades  mainly  into  monomeric  silicic  acid,  Si(OH)4, the most natural 
form of Si in the environment and very important in human physiology in protecting 
against the poisonous effects of aluminium (Popplewell et al., 1998), is an important 
feature that contributes even further to the PSi apparent biocompatibility. It has been 
reported that the average daily intake of Si in the Western World is approximately 20?50 
mg/day (Jugdaohsingh et al., 2002; Jugdaohsingh et al.,  2004)  and  that  Si  is  an  essential  
nutrient for the human body. Blood concentrations of Si(OH)4 have been found to be 
slightly above the typical values of 1 mg/L (Popplewell et al., 1998) and, most importantly, 
all Si(OH)4 was shown to be efficiently excreted in urine (Bonanno and Delouise, 2010).  
 
The PSi degradation from membranes into Si(OH4) and its impact on the biocompatibility 
of PSi in human ocular cells both in vitro and in vivo, in the rat eye has been evaluated. 
(Low et  al., 2009). Also, regarding ophthalmic applications, PSi encapsulated in 
microfibers of the biodegradable polymer polycaprolactone (PCL) was appraised, using 
both a cell attachment assay with epithelial cells and an in vivo assessment of 
biocompatibility in rats (Kashanian et  al., 2010). The study also assessed the surface 
chemistry of PSi dissolution kinetics, with the authors reporting that the composite material 
did not elicit any inflammatory response or infection. The covalent attachment of 
poly(ethylene) glycol (PEG) molecules to the PSi surface was also found to modulate the 
degradation kinetics of PSi structures (Godin et  al., 2010). Different molecular weight 
PEGs (245-5000 Da) were employed with the authors reporting that the in vitro 
degradation of the PEGylated particles (30–50 nm pores) in phosphate buffer solution 
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(PBS, pH 7.2) and serum at 37 ?C showed slower particle degradation with increasing PEG 
molecular weight.  
 
PSi has also been found to support living cultures of mammalian tissues. For example, 
adhesion of Chinese hamster ovary cells and rat hippocampal neurons (B50) (Sapelkin et 
al., 2006), adhesion of rat pheochromocytoma (PC12, a neurosecretory cell line) and 
human lens epithelial cells (HLE) (Low et al., 2006) and nerve tissue to PSi surfaces 
(Johansson et al., 2009) have been already successfully demonstrated . Adhesion studies of 
PSi to biological surfaces have also shown the immunogenic effect of micro- and 
nanostructured Si-based surfaces for in vivo therapeutic or sensing applications. Ainslie and 
co-workers (Ainslie et  al., 2008) have studied the immune responses of four Si surfaces 
(nanoporous, microstructured, nanochanneled, and flat) in human blood derived monocytes 
after 48 h of exposure. They found that the immunogenicity and biocompatibility of flat, 
nanochanneled, and nano-PSi towards human monocytes were approximately equivalent to 
tissue culture polystyrene, and the formation of reactive oxygen species (ROS) was not 
found to be a prerequisite for inflammation in the Si-based surfaces. 
 
The PSi prepared by electrochemical anodization of crystalline Si in HF-containing 
electrolytes, has been found to be a good reducing agent. Both the Si–H species on the 
surface and the skeleton consisting of elemental Si have reduction potentials sufficient to 
reduce many organic molecules (Wu et al., 2011). This potential for generating highly 
reactive singlet oxygen from PSi particles in ethanol and aqueous media has been exploited 
for phototoxicity in cancer cells, leading to remarkable cell death in HeLa or NIH-3T3 cells 
(Xiao et al., 2011). The in vitro cytotoxicity of PSi microparticles (1–75 ?m) with different 
surface chemistries (TOPSi, TCPSi and THCPSi) in Caco-2 cells was reported to follow 
both concentration- and size-dependent trends (Santos et al., 2010). The study showed that 
TOPSi surface chemistry induced a less pronounced cytotoxic response than TCPSi and 
THCPSi microparticles, and the suggested mechanisms of cytotoxicity included 
mitochondrial disruption, ATP depletion, ROS, and cell apoptosis. Together with its 
biocompatibility and the ability to yield harmless degradation products, the high surface 
area and high porosity of the PSi materials also raised the possibility to load drug 
compounds within its pores (Prestidge et al., 2007; Anglin et al., 2008). 
 2.2.3.2 Drug delivery  
The attainment of a controlled and localized release of drug compounds within the body is 
of paramount importance for increasing the efficacy and decreasing the potential side 
effects of therapy (Braeckmans et al., 2002; Brigger et al., 2002). The research over PSi-
based materials for drug delivery applications emerged in the late 1990´s with reports of Si 
nanopore membranes (Desai et al., 1999), although it became more prevalent after the year 
2000 (Salonen and Lehto, 2008). One major advantage of the PSi materials is that they can 
be tailored for continuous or triggered drug release, depending on the application.  
 
For example, PSi nanostructures can display responsive properties to chemical stimuli such 
as pH (Xue et  al., 2011). The loading of compounds into a PSi host can be carried out 
using different strategies, which can be grouped into the following general categories: 
covalent attachment, physical trapping and adsorption (Anglin et  al., 2008). The drug 
loading is affected by several factors involved in the process. These include pH 
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dependency, temperature, and time, but the most vital factor is the possible chemical 
reactivity of the drug loading solution with the PSi surface. Some drugs, like antipyrine, 
catalyze oxidation of the as-anodized PSi (Salonen et al., 2005), and some other drugs, like 
ranitidine, strongly react even with TOPSi in methanol solution (Salonen et al., 2008).  
 
By combining the results of thermogravimetry and differential scanning calorimetry 
(DSC), the amount of drug confined within the pores of PSi determined (Lehto et al., 
2005). The thermodynamic states of ibuprofen loaded into PSi were also subsequently 
characterized using thermal analysis and nitrogen sorption (Riikonen et al., 2009). The 
authors found three different thermodynamic states of ibuprofen in the samples: (1) a 
crystalline state in the surface outside the pores; (2) a crystalline state in the center of the 
pores; (3) and a disordered state between the pore wall and the crystalline core. The results 
supported the assumption of the existence of a layer of disordered ibuprofen adjacent to the 
pore wall (i.e., ?-layer) of around 2 nm, in which the thickness is not strongly dependent 
upon the pore size. Consequently, an increase in solubility and dissolution rate of the drug 
is achieved, as a result of the high lattice energy of the drug molecule inside of the pores 
(Yu, 2001; Huang and Tong, 2004). The tunable pore sizes and volumes were also found to 
control the amount of drug loaded within the pores and allow temporal release profiles 
(Anglin et al., 2004). For example, six different types of PSi microparticles – as-anodized, 
TCPSi, TOPSi, annealed-TCPSi, annealed-TOPSi and THCPSi) – were prepared to 
evaluate the effect of the surface treatment and pore size on the dissolution properties and 
stability of PSi microparticles (Limnell et al., 2007). It was observed that the hydrophilic 
TCPSi particles were the most stable and induced the fastest ibuprofen dissolution, and no 
changes in the release profiles of ibuprofen were observed after three months of stability 
testing (30 °C, 56% relative humidity). 
 
The paracellular delivery of insulin across an intestinal Caco-2 cell monolayer using 
microfabricated PSi particles was one of the first examples of drug delivery using this 
material (Foraker et al., 2003). The authors found that the permeation of insulin across 
Caco-2 cell monolayers was significantly enhanced and represented a 10-fold increase 
when compared with insulin delivered through oral formulations and up to 100-fold 
increase when compared with formulations without permeation enhancers. The release of 
the steroid dexamethasone from freshly etched, hydrogen-terminated PSi films was also 
found to be faster due to the chemical instability of PSi at physiologic pH, and the 
mechanism of drug release was suggested to be a combination between drug leaching and 
PSi matrix dissolution (Anglin et al., 2004). Protein-conjugated microfabricated PSi 
systems for oral drug delivery have also been found to modulate the adhesion of these 
reservoir systems to the GI walls, potentially improving their drug delivering abilities 
(Ahmed et al., 2002).  In a study involving a two-layer PSi matrix with 2 µm pores and 200 
nm thick layer loaded with doxorubicin (an anticancer drug), the authors found that the Si 
matrix exhibited a time-dependent drug release profile modulated by the thickness of the 
PSi layer (Vaccari et al., 2006).  
 
Studies involving TCPSi and TOPSi microparticles for oral administration have also been 
conducted using five model drugs: antipyrine, ibuprofen, griseofulvin, ranitidine and 
furosemide (Salonen et al., 2005). The drug compounds were loaded into TCPSi and 
TOPSi microparticles and were investigated for their drug releasing behavior and stability 
in the presence of aqueous or organic solvents. The surface properties of the particles, the 
chemical nature of the drug and the drug loading solution, determined the compound 
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affinity towards the mesoporous particles’ pores. The release rates of the loaded drugs from 
the TCPSi microparticles were also found to depend on the characteristic dissolution 
behavior of the drug substance in question: when the dissolution rate of the free/unloaded 
drug was high, the microparticles caused a delayed release. Another study concerning 
TCPSi microparticles loaded with furosemide, showed that both drug release/dissolution 
and permeation across a Caco-2 cell monolayer at pH values of 5.5, 6.8 and 7.4 were 
enhanced (Kaukonen et  al., 2007). The authors reported a 5-fold increase in furosemide 
permeation from the TCPSi-loaded particles when compared with the pre-dissolved drug.  
 
Nanostructured TOPSi particles were also investigated for their effectiveness as drug 
carriers for sustained release of the antibacterial agent triclosan (Wang et al., 2010). The 
study reported an enhanced inhibitory activity over a 100 day period. The same type of 
surface-treated particles was also used in order to improve the pharmacokinetic behaviour 
of indomethacin (IMC), a non-steroidal anti-inflammatory drug (Wang et al., 2010). The 
dissolution profiles at pH 7.2 showed a rapid dissolution for both the IMC loaded in TOPSi 
particles and a commercial Indocid? formulation within the first 5 min (85 and 95 wt-% 
dissolved, respectively) compared to pure crystalline drug. The study also reported that the 
IMC plasma concentrations of fasted Sprague-Dawley rats showed significant increase in 
both Cmax and bioavailability. Another study was conducted using two different strategies 
for loading doxorubicin: (1) physically adsorbed to PSi with 30?50 µm in size and 20?30 
nm pore diameter, and (2) covalently attached to a 10-undecenoic acid linker, which was 
attached by thermal hydrosilylation and grafted to the PSi surface (Wu et al., 2008). The 
authors reported that for the physically adsorbed drug, a rapid and complete drug release 
was observed within 24 h, whereas particles containing a combination of covalently 
attached and physioadsorbed doxorubicin displayed a gradual release over a period of > 24 
h. In the case of the covalent attached doxorubicin, the drug was released only when the 
covalent bonds were broken or the PSi matrix was oxidized and degraded. The doxorubicin 
that was covalently attached to the particles showed a continuous and slower release for > 5 
days. The drug release was proposed to be a two-step mechanism involving oxidation and 
subsequent dissolution of the PSi matrix.  
 
Besides small molecules, peptide delivery from PSi materials has also been conducted.  
The peptides Melanotan II (Kilpelainen et al., 2011), ghrelin antagonist (Kilpelainen et al., 
2009), and PYY3-36 (Kovalainen et  al., 2011), human serum albumin (Zangooie et al., 
1998), papain and gramicidin A (Prestidge et al., 2007; Prestidge et  al., 2008), have all 
been loaded into PSi and investigated both in vitro and in vivo. For example, the in vitro 
release of the protein papain from PSi powders has shown both a burst and sustained 
release depending on the PSi surface modification and loading degree (Prestidge et al., 
2007). Importantly, the interactions between the PSi surfaces and the loaded 
peptides/proteins were found to be crucial and to define the success of loading and/or 
release from the particles. Other authors loaded an antibiotic (vancomycin) into PSi films 
and trapped the peptide by capping the films with a layer containing bovine serum albumin 
(BSA), in order to obtain a pH-triggered release system (Perelman et al., 2008). At pH 4.0 
the drug was not released from the films of different thicknesses, whereas when the pH was 
increased to 7.4, BSA was dissolved and vancomycin was released into the solution.  
TOPSi surfaces were also shown to effectively control protein interactions, which dictate 
adsorption, protein structure, and bioactivity (Jarvis et al., 2010). Adsorption mechanisms 
of lysozyme, papain, and human serum albumin were shown to be controlled by both 
protein structure and PSi surface chemistry, via hydrophobic interactions and electrostatic 
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attractions. High protein adsorption onto unoxidized PSi (240?610 ?g/m2) was attributed to 
predominately hydrophobic interactions, which resulted in structural changes of the 
adsorbed proteins and significant loss of bioactivity. 
2.2.3.3 Cellular interactions 
When nanoengineered carriers are administered in the body, they encounter several 
physiological barriers and interact extensively with the cellular environment. Throughout 
their translocation the particles will encounter a number of the organism’s defenses that can 
eliminate, sequester, or dissolve the particles. In addition, cells and tissues have effective 
antioxidant defenses that deal with ROS generation (Figure 2). The hierarchical oxidative 
stress model hypothesizes that materials can elicit different types of responses at different 
levels that might even not be cytotoxic, but nonetheless represent an aggression to the cell 
(Nel et al., 2006). The first tier of response to the foreign material involves the anti-oxidant 
defense pathway, which leads to the activation of the nuclear factor (erythroid-derived 2)-
like 2 (Nrf-2), responsible for the expression of various genes including those encoding 
several antioxidant enzymes. The final outcome of this pathway is the activation of Phase 
II enzymes, which are responsible for conjugation reactions and usually detoxicating in 
nature. The second tier of response regards to the eliciting of inflammatory reactions, with 
the activation of the redox-sensitive transcriptor factors, nuclear factor kappa B (NF-?B), a 
key regulator of immunity, inflammation and cell proliferation which also regulates the 
mitogen activated protein (MAP) kinase pathway (Müller et  al., 1997) and the activator 
protein 1 (AP-1), also responsible for apoptosis (Ameyar et al., 2003). The activation of 
these transcription factor leads to final release of chemokines and cytokines in the body. 
The final tier of aggression might result in cytotoxicity involving the mitochondrial 
permeability transition pore (PT pore), an opening in the mitochondrial membrane which 
results in a sudden permeability increase of the inner mitochondrial membrane to solutes 
and some proteins, thereby disrupting the inner transmembrane potential. The PT pore 
might be accompanied by colloidosmotic swelling and uncoupling of oxidative 
phosphorylation, as well as by the loss of low molecular weight matrix molecules such as 
calcium and glutathione. The outcome of this cascade of phenomena that occur when the 
cytotoxic path is activated is apoptosis, or programmed cell death (Trachootham et al., 
2008).  
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Figure 2 Schematic diagram of the hierarchical oxidative stress mode. Modified from Nel et al., 
2006. Copyright © (2006) AAAS. Reprinted with permission. 
The thorough list of all cellular models tested with Si materials is quite extensive but 
nonentheless, some studies conducted have been of special interest in the field. A report on 
the p-type, flat, nanoporous, micropeaked and nanochanelled Si surfaces in contact with a 
human blood monocyte model, regarding cytokine and chemokine analysis as well as ROS 
assessment and cytotoxicity, has showed that the immunogenicity and biocompatibility of 
the PSi surfaces towards human monocytes is approximately equivalent to tissue culture 
polystyrene (Ainslie et  al., 2008). Also, relating to the generation of ROS, other authors 
have reported that as-anodized PSi microparticles produced ROS, which interacted with the 
components of the cell culture medium, leading to the formation of cytotoxic species (Low 
et al., 2010). The oxidation of PSi microparticles not only mitigated, but also abolished any 
toxic effects. Furthermore, several reports on cell adhesion of PSi wafers have also been 
published (Bayliss et al., 1999; Bayliss et al., 2000; Sapelkin et  al., 2006), consistently 
showing that silicon substrates are not toxic to the cells, which remain viable in terms of 
respiration and cell membrane integrity. 
 
PSi particles have revealed their drug delivering potential by exploring the possibility to 
assemble in multistage delivery devices. The development of PSi microparticles as a 
multistage delivery system loaded with one or more types of second stage particles has 
been given substantial attention by Prof. Ferrari’s group (Tasciotti et al., 2008; Serda et al., 
2010; Tanaka et al., 2010; Godin et al., 2011). This technology relies on biodegradable 
stage 1 microparticles (S1MPs) composed of lithographically engineered PSi with defined 
shapes, sizes and porosities (Serda et al., 2009; Chiappini et al., 2010) which enables them 
to attain optimal margination, firm adhesion, and tunable internalization properties 
(Decuzzi et al., 2005; Decuzzi and Ferrari, 2008; Decuzzi et al., 2009). The S1MPs can be 
subsequently loaded with several types of other smaller particles or stage 2 nanoparticles. 
(S2NPs). The hemispherical shape of these carriers was found to be beneficial in terms of 
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margination towards the vasculature wall in circulation, biodistribution, endothelial 
adhesion, and cell internalization when compared with spherical carriers (Decuzzi et  al., 
2004). These rationally-designed carriers were further employed in personalized targeting, 
overcoming barriers such as enzymatic degradation, vascular endothelium crossing, and 
molecular efflux pumps. The ability of these logic-embedded vectors to surmount 
biological barriers, such as cellular membranes, hemorheology, and reticuloendothelial 
system (RES) uptake was confirmed in a number of studies by the same group (Serda et al., 
2009; Serda et al., 2009; Godin et al., 2010). Preclinical studies on the quasi-hemispherical 
and discoidal PSi particles with dimensions of 600 nm–3.2 µm (Chiappini et al., 2010) 
have shown that the PSi microparticles are phagocytosed by vascular endothelial cells 
(Serda et al., 2009; Serda et al., 2009; Serda et al., 2009), and accumulate mainly in 
phagosomes (Serda et al., 2009). The main advantage of these systems is that they can be 
loaded  with  many  different  agents,  such  as  proteases,  contrast  agents,  siRNA,  and  
therapeutic genes, rendering them a very versatile platform for drug delivery and imaging 
purposes. 
 
The cell morphology and function was also shown to be greatly influenced by both the 
substrate surface characteristics and the presence of a 3D collagen mesh in PC12 cells 
(Lopez et al., 2006). Other authors (Alvarez et al., 2009) studied the attachment and 
viability  of  primary  cells  with  PSi  films  of  various  surface  chemistries  (SiO2, decyl, 
undecanoic acid, and oligoethylene glycol), and evaluated their ability to retain optical 
reflectivity properties relevant to molecular biosensing. The hepatocytes were found to 
adhere better to surfaces coated with collagen and chemical modification of PSi did not 
affect the rat cells. In addition, the PSi samples hydrosilylated with a hydrophilic, 
carboxylic acid species (collagen-coated undecanoic acid modified) showed the best 
stability and compatibility with primary rat hepatocytes, similar to those observed for 
standard culture preparations on tissue culture polystyrene. 
  
A study using an electrospinning method to produce 3D-fibrous structures of PSi/PCL for 
orthopedic purposes has found that the highly porous and slowly degrading PSi/PCL 
micro-fibrous scaffolds supported human mesenchymal stem cells and bone marrow-
derived mouse stromal cells in their ability to proliferate, migrate, and differentiate (Fan et 
al., 2011).  
2.2.3.4 Protein coating 
Besides the advantages described above, PSi surfaces can made even more biocompatible 
and chemically stable by self-assembling a biofilm of proteins, such as hydrophobins, 
(HFBs) onto its surface (De Stefano et al., 2007; De Stefano et al., 2008; De Stefano et al., 
2009). Hydrophobins are a family of surface active proteins of fungal origin that have the 
ability to form self-assembled layers on hydrophobic materials and modify the surface 
binding properties, thus turning hydrophobic surfaces into hydrophilic (Hektor and 
Scholtmeijer, 2005; Linder, 2009; Laaksonen et al., 2010; Varjonen et al., 2011). As a 
result, the wettability properties of PSi can be altered (De Stefano et al., 2009), leading to 
the production of a chemically and mechanically stable homogenous monolayer of self-
assembled proteins with improved characteristics in terms of surface interaction. In 
addition to the efficient dispersion in aqueous media of nanomaterials such as single-walled 
carbon nanotubes (Kurppa et al., 2007) or Teflon® powders (Lumsdon et al., 2005), these 
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proteins have also been reported to stabilize drug nanoparticles by acting as surfactants 
improving the dissolution of water insoluble drugs (Akanbi et al., 2010; Valo et al., 2010) 
and for drug immobilization on nanofibrilar cellulose using an HFB engineered variant 
(Valo et al., 2011). The ability to modulate protein adhesion and wettability in the HFB-
coated surfaces (Hektor and Scholtmeijer, 2005), suggests the possibility to modify the 
interaction of PSi surfaces with endogenous proteins when administered in the body 
(Sarparanta et  al.,  2011).   Furthermore,  the  HFB  was  also  found  to  play  a  role  in  the  
prevention of host immune response to fungal spores (Aimanianda et al., 2009), leading to 
the hypothesis that these proteins could confer shielding against immune-system 
recognition in vivo.  
 
Following in vitro testing, the in vivo assessment of a potential drug carrier is crucial in 
order to understand the pharmacodynamics and biodistribution of such carrier and 
anticipate its harmful reactions. The accumulation and clearance of nanoparticulate systems 
are also critical parameters to address when such carriers are envisioned to be translated to 
the clinic.  
2.2.3.5 Biodistribution, accumulation and clearance 
Although essential, biodistribution studies concerning PSi particles have been scarce so far. 
From the several reports already published regarding in vivo PSi testing, most deal with PSi 
microparticles and implants (Table 3). 
Table 3 Type of PSi materials used for in vivo studies and type of analysis conducted. Adapted 
from Santos et al., 2011.Copyright © (2011) Bentham Science Publishers. Reprinted 
with permission. 
Material type In vivo model Aim Reference 
p-type, thermally 
oxidized and thermal 
hydrosililyzed 1-270 µm 
particles 
Rabbit eye 
vitreous 
Particle degradation and 
cytotoxicity 
(Cheng et 
al., 2008) 
boron-doped, 50 and 200 
nm ultrasonicated PSi 
particles 
A20 and A20-
grafted Balb/c mice 
increase peptide 
bioavailability, targeting 
enhancement and cytotoxicity 
(De Angelis 
et al., 2010) 
p++-type, 1.6×1.6 µm 
semi-spherical, 1.6×0.3 µm 
discoidal and 1×1 µm 
cylindrical PSi particles 
MDA-MB-231-
grafted nu/nu nude 
mice 
Biodistribution, size and 
shape dependency 
(Decuzzi et 
al., 2010) 
32P-Brachysil™ 20 µm 
microparticles 
human clinical 
trial – hepatcellular 
carcinoma 
Safety, tolerance and anti-
tumor efficacy 
(Goh et al., 
2007) 
p-type 200 µm pSi–PCL 
electrospun fibers 
HLE and 
Sprague–Dawley 
rats 
Dissolution kinetics, 
attachment, in vivo ocular 
inflammation and 
neovascularization 
(Kashanian 
et al., 2010) 
p+-type, THCPSi 38-53 
µm particles 
Wistar rats and 
Balb/c mice 
Peptide (Ghrelin antagonist) 
release, effect on blood pressure, 
food intake and cytokine release 
(Kilpelainen 
et al., 2009) 
p+-type, THCPSi 38-53 Wistar rats and Peptide (Melanotan II) (Kilpelainen 
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µm particles Balb/c mice release, effect on heart rate and 
water intake 
et al., 2011) 
n-type, TOPSi and 
TOPSi-aminosilanised 1-60 
µm membranes 
HLE, human 
corneal cells and 
Sprague–Dawley 
rats 
Biocompatibility, dissolution 
and cellular growth 
(Low et al., 
2009) 
p++-type, 130-180 (126) 
nm biopolymer-coated PSi 
particles 
MDA-MB-435  
and MDA-MB-435 
grafted-BALB/c 
mice 
Degradation, cytotoxicity, 
drug (doxorubicin) release, 
biodistribution, in vivo imaging 
(Park et al., 
2009) 
p-type, plane and PSi 
4×4×0.5 mm implants 
Rat (abdominal 
wall) 
Capsule formation, thickness 
and immunoreactivity 
(Rosengren 
et al., 2000) 
p++-type, 1.6 µm 
diameter APTES-modified, 
targeted-liposomal siRNA 
loaded PSi particles 
HeyA8-Lc and 
Skov3ip1-Lc and 
NCr-nu mice 
Biodistribution, 
biodegradation, sustained targeted 
siRNA delivery, in vivo protein 
knockdown, cell proliferation and 
tumor growth 
(Tanaka et 
al., 2010) 
p+-type, 13.6 µm TOPSi 
particles 
Sprague-
Dawley rats 
Drug (indomethacin) release, 
in vivo absorption, in vitro-in vivo 
correlation (IVIVC) 
(Wang et 
al., 2010) 
p++-type, 1.6 µm 
diameter oxidized negatively 
charged and APTES-
modified positively charged 
PSi particles 
FBV mice 
Cytotoxicity, cytokine 
release, tissue accumulation, renal 
and hepatic function 
(Tanaka et 
al., 2010) 
32P BioSilicon™ 
HepG2 and 
2119 grafted-
BALB/c mice 
Time-response tumor volume, 
histology 
(Zhang et 
al., 2005) 
 
One of the pioneering reports of luminescent PSi nanoparticles (LPSiNPs) prepared by 
electrochemical etching of single-crystal Si wafers for i.v. delivery was first published in 
2009 by the group of Prof. Sailor (Park et  al., 2009). The authors fabricated PSi particles 
under 200 nm in size and then loaded them with doxorubicin. They were able to 
demonstrate that the drug was slowly released under physiological conditions, reaching a 
maximum within 8 h and that no significant toxicity could be related to the degradation 
product of the material in the animal tissues. When mice were injected i.v. with 
suspensions of the nanoparticles (20 mg/kg), they were able to clear the particles from the 
body within 4 weeks. Interestingly, such system was also demonstrated to be suitable for in 
vivo imaging after intra muscular and sub-cutaneous injections in nude mice. The 
monitoring of the particles by near-infrared fluorescence showed that the adsorption of a 
dextran layer onto the surface of the particles with 126 nm in diameter, pore diameters of 
5?10 nm and a zeta potential of –52 to –39 mV, increased the stability of the material, 
allowing better and longer-lasting visualization in the animal body after administration. 
The biodistribution and histological studies in mice 24 h after injections showed that the 
LPSiNPs particles accumulated preferentially in the spleen rather than in the liver, whereas 
the dextran-coated LPSiNPs accumulated more in the liver than in the spleen. The injection 
of the dextran-coated LPSiNPs into the nude mice bearing a tumor led to an accumulation 
of the nanoparticles in the tumor, aiding its visualization.  
 
A report on the biocompatibility and safety of i.v. administered PSi structures with a 
diameter of 1.6 ?m and pore size of 36 nm, negatively (?32 mV) and positively (8.7 mV) 
charged, after acute single doses (107, 108, 5×108 PSi particles/animal) and subchronic 
multiple doses (108 PSi particles/animal/week for 4 weeks) in immunocompetent mice was 
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subsequently published (Tanaka et al., 2010). In this study, discoidal-shaped particles were 
used (Ferrari et  al., 2011), and the histopathological evaluation revealed that the PSi 
particles accumulated primarily in the liver and spleen with no indication of leukocyte 
infiltration. No significant innate or adaptative inflammatory responses were observed 
following either the acute or sub-chronic administration. Furthermore, the PSi particles did 
not change plasma and lactate dehydrogenase (LDH) levels of renal and hepatic 
biomarkers, as well as of 23 plasma cytokines, which showed that the particles were well 
tolerated both in single and sub-chronic multiple administrations. Another study 
concerning the biodistribution of quasi-hemispherical, discoidal and cylindrical particles 
after intravascularly injection into tumor-bearing mice was also published (Decuzzi et al., 
2010). The authors demonstrated that for the quasi-hemispherical beads, the number of 
particles accumulating in the non-RES organs reduced monotonically as the diameter of the 
particles increased, suggesting the use of smaller particles to provide a more uniform tissue 
distribution. However, discoidal particles have also been observed to accumulate more than 
others in most of the organs but the liver, where cylindrical particles are deposited in a 
larger extent. The use of near-infrared imaging for non-invasive in vivo assessment of the 
biodistribution of nanoporous discoidal Si particles has also been employed, suggesting 
that particles predominantly accumulated in the liver and spleen after 24 h (Tasciotti et al., 
2011). Proteomic analysis of intravascularly injected cationic and anionic discoidal PSi 
particles showed that cationic microparticles displayed a 25-fold greater abundance of 
immunoglobulin light variable chain, fibrinogen, and complement component 1 compared 
to their anionic counterparts. The anionic microparticles were found to accumulate equally 
in murine liver and spleen, whereas cationic microparticles showed preferential 
accumulation in the spleen (Serda et  al., 2011). Immuno-histochemistry supported 
macrophage uptake of both anionic and cationic microparticles in the liver, as well as 
evidence of association of cationic microparticles with hepatic endothelial cells. Particulate 
systems have different stability, behaviour in the biological microenvironment, and cellular 
distribution according to their size, morphology and chemical constitution (Moghimi et al., 
2005).  Even  at  a  nanoscale,  biological  compounds  will  interact  very  differently  with  the  
cellular environment compared with non-biological compounds such as metals, metalloids 
or synthetic polymers (De Jong and Borm, 2008). Therefore, a thorough understanding of 
particle-cell interaction should be developed before a drug carrier can come into the 
clinical setting. 
 
Safety and biocompatibility of PSi engineered structures are, therefore, a requirement both 
in manufacture and, more importantly, when in vivo exposure or administration is 
concerned. In this context, there are several different responses that these nanoengineered 
materials may induce when in contact with cells. Consequently, a full characterization of 
the toxicological issues regarding these structures is crucial in the pre-clinical stage. 
Furthermore, even when all in vitro studies are conducted, a thorough understanding on the 
biodistribution of these materials is critical in order to validate them as potential drug 
carriers and to envision their human application. 
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3 Aims of the study 
The aim of this thesis was to investigate the biocompatibility of PSi particulates with 
different cell models and to biofunctionalize the PSi surface with a self-assembled 
functional protein coat.  
 
The specific objectives of this study were: 
 
1. To address the biocompatibility, inflammatory response, oxidative stress 
and drug permeation properties of thermally oxidized PSi particles (I). 
 
2. To investigate the biocompatibility, inflammatory response and oxidative 
stress of thermally hydrocarbonized PSi particles, as well as to evaluate 
thes biodistribution in a rat model (II). 
 
3. To develop a method for reproducibly coat thermally hydrocarbonized 
PSi microparticles with a self-assembling hydrophobin class II (HFBII) 
protein and to investigate their biocompatibility and drug release 
properties (III). 
 
4. To characterize HFBII-coated thermally hydrocarbonized PSi 
nanoparticles in terms of their biocompatibility and cellular association, 
as well as to investigate their drug permeation properties (IV). 
 
5. To assess the gastro-retentive properties of HFBII-coated thermally 
hydrocarbonized PSi nanoparticles and their biocompatibility in a gastric 
cell line (V). 
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4 Experimental 
Detailed descriptions of the methods, suppliers of the materials and the equipment used in 
this work can be found in the respective original publications (I-V). The PSi-based 
materials (I-V)  were  produced  at  the  Laboratory  of  Industrial  Physics,  Department  of  
Physics  and  Astronomy,  University  of  Turku.  The  radiolabelling  of  the  particles  and  
HFBII, and the animal experiments (II, IV and V)  were  conducted  at  the  Laboratory  of  
Radiochemistry, Department of Chemistry, University of Helsinki. 
4.1 Materials and methods 
4.1.1 Mesoporous silicon particles (I-V) 
The PSi particles were prepared from boron doped monocrystalline Si wafers ?100? of p+-
type with resistivity values of 0.01?0.02 ?cm. The anodization of the wafers was done in a 
1:1 (v/v) HF (38%)?ethanol (EtOH) mixture in a Teflon® container. For the microparticles 
(I, II and III), the free-standing films were obtained by etching the wafer for 40 min using 
a constant current density (50 mA/cm2) followed by the detachment of the porous film 
from the substrate by abruptly increasing the current density to the electropolishing region. 
The films were then dry milled in a high energy ball mill system for a short period in an 
agate grinding jar, after which they were dry sieved repeatedly in mesh sieves until the 
desired size fractions were obtained. Each fraction of the microparticles was then wet 
sieved with absolute EtOH to separate the larger aggregates and dried at 65 ºC. 
 
For the nanoparticles, the electrochemical etching consisted of the application of three 
different current pulses: (1) a first low current pulse to produce a mesoporous structure; (2) 
a second shorter pulse near the electropolishing region, which produced highly porous and 
mechanically fragile layers; and (3) a third zero-current pulse to remove the possible 
electrolyte concentration gradients in the pores formed during the high current pulse, 
before a new etching cycle starts. Finally, an increase in the current intensity near the 
electropolishing region was used in order to separate the multilayer film from the substrate. 
4.1.1.1 Particle surface treatments (I-V) 
The as-anodized hydrogen terminated surface of PSi is prone to oxidation, and therefore, 
needs to be surface treated in order to be stabilized. Before the surface stabilization, all 
particles  were  either  mesh  sieved  (microparticles)  or  wet-sieved  and  centrifuged  
(nanoparticles) to the desired size fractions. From the surface treatments that can be 
employed  for  the  stabilization  of  the  particles,  the  thermal  oxidation  (I) and the thermal 
hydrocarbonization (II-V) were utilized and studied in this dissertation. With the exception 
of thermally oxidized particles, prior to any surface treatment, all the sieved particles were 
immersed in HF in order to remove the surface oxide formed during the milling. For the 
thermal oxidation , the temperature treatment consisted in exposing the particles to 300 ºC 
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for 2 h at ambient air. The particles obtained in this fashion, TOPSi, have oxidized 
terminated Si-O bonds and are hydrophilic. The thermal hydrocarbonization treatment 
consisted of exposing the particles to a 1:1 (v/v) flow mixture of N2 and acetylene for 15 
min at room temperature, followed by 15 min at 500 ºC, and then cooling down to room 
temperature under a N2 flush. This type of treatment protects even further the particles, 
THCPSi, against oxidation, but on the other hand, yields very electrostatic particles, with 
hydrophobic Si-C-H terminated bonds.  
4.1.1.2 Particle drug loading (I, III and IV) 
The drugs were loaded into the pores of the PSi particles using an immersion method. This 
method consisted in dissolving the drug model compounds, griseofulvin (I)  and IMC (III 
and IV), in an appropriate solvent at the following concentrations: griseofulvin (I) 75 
mg/mL in dichloromethane (DCM) and IMC 175 mg/mL in dimethylsulfoxide (DMSO; III 
and IV). The loading was carried out at room temperature for both griseofulvin and IMC 
with a ratio of 0.5 mL of drug solution to 15 mg of particles and 0.5 mL of drug solution to 
85 mg of particles, respectively. The loading time was 3 h, after which the particles were 
centrifuged and the excess of loading solution removed. The griseofulvin-loaded particles 
were dried at 65 ºC at atmospheric pressure and the IMC-loaded particles were vacuum 
filtered from the loading solution at 40 ºC under vacuum (< 2 mbar). 
4.1.1.3 Particle 18F-radiolabelling (II and V) 
Fluorine-18 was produced in a 18O(p,n)18F reaction on a IBA Cyclone 5/10 cyclotron. To 1 
mg of THCPSi nanoparticles suspended in anhydrous dimethylformamide (DMF) it was 
added 500 µL of 4% (v/v) acetic acid and 0.5?1 GBq of fluorine-18 as [18F]KF/Kryptofix 
2.2.2 in 100 µL of DMF. The solution was then heated at 120 ºC for 15 min. The 
radiolabeled nanoparticles were purified with sequential washes in absolute ethanol, 
ultrapure water and 1×Hank’s Balanced Salt Solution (HBSS, pH 7.4). The particles were 
then centrifuged at 29,000 g,  the  supernatant  was  changed  and  the  particles  were  re-
suspended by sonication between washes. The final formulation was prepared in 5% 
Solutol-1×HBSS (pH 7.4). 
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4.1.2 Model drug compounds (I, III and IV) 
Model drug compounds used in the studies were griseofulvin (I)  and  IMC  (III and IV). 
The chemical structures and physicochemical properties of the drugs are depicted in Table 
4. The drugs tested are similar in molecular weight and pKa, and are both poorly soluble 
but highly permeable compounds (Biopharmaceutical Classification System II). 
 
Table 4 Properties and structures of the model drug compounds (I, III and IV). 
Drug compound Structure Molecular 
weight 
pKa Publication 
Indomethacin 
(IMC) 
 
357.8 4.5 III, IV 
Griseofulvin 
 
 
352.8 
 
 
4.4 I 
4.1.3 Hydrophobin II coating (III-V) 
The Hydrophobin II (HFBII) was first purified from the culture supernatant of a 
Trichoderma reesei cultivation and purified by surfactant extraction (Linder et al., 2001). 
For  the  coating  of  THCPSi  with  HFBII  (III-V), a HFBII solution (0.5?1 mg/mL) was 
prepared in a glass tube using McIlvane’s buffer (pH 4.0) as a solvent. Empty or drug-
loaded particles were then added to the HFBII solution at a mass ratio of 4:1 
(particle/HFBII) and gently stirred for several minutes until the particles were dispersed in 
solution, followed by an incubation at 80 ºC for 30 min. The solution was then centrifuged 
at 6,000 g for 2 min and the entire supernatant removed. The particles were then washed 
four times with 1 mL of ultrapure water with subsequent centrifugation cycles at 6,000 g 
for 2 min for every wash. The particles were then dried at 60 ºC and were either re-
suspended in ultrapure water, HBSS or used as a dry powder. The quantification of HFBII 
protein was carried out using the bicinchoninic acid (BCA) assay (III-V) or high 
performance liquid chromatography (HPLC; IV and V). 
4.1.3.1 HFBII 125I-radiolabelling (IV and V) 
The  HFBII  was  radiolabeled  with  125I  in  10-5 M  NaOH  (pH  8-10  reductant-free)  using  a  
standard procedure for radioiodination with the Bolton-Hunter method (Bolton and Hunter, 
1973). The N-succinimidyl-3-(hydroxyphenyl)propionate (SHPP) was synthesized from 3-
(4-hydrophenyl)propionic acid and N-hydrosuccinimide. The purity of SHPP-125I was then 
verified with thin layer chromatography (TLC) on a 60 F254 plate developed with 9:1 (v/v) 
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ethyl acetate-methanol. A volume of 50 µL of 1mg/mL of HFBII in 100 mM sodium-
borate buffer, (pH 8.5) was added to the dried SHPP-125I and the reaction mixture was 
incubated at 40 ºC for 45 min. The HFBII-125I was subsequently purified on a G-25 column 
preconditioned with 8 mL of McIlvane buffer (pH 4.0). The product was eluted with 3 mL 
of the buffer collecting 200 µL fractions. The fractions were measured on a dose calibrator 
and peak fractions pooled. A 0.2-µL sample from the pooled peak fractions was spotted on 
a chromatography paper and developed with 50:50 (v/v) methanol?water for determination 
of radiochemical purity of HFBII-125I. The TLC plate and chromatography paper were 
subsequently exposed to a digital imaging plate for 48 h. The imaging plate was scanned on 
a scanner and the autoradiographs analyzed with imaging software. Immediately after 
pooling, 0.1 mg of HFBII carrier in McIlvane buffer (pH 4.0) was added to the HFBII-125I 
solution  to  prevent  adsorption  to  the  vial  walls.  The  HFBII  was  quantified  against  a  
standard series by HPLC.  
4.1.4 Cell culture (I-V) 
Human colon adenocarcinoma Caco-2 (I-IV),  Human  gastric  adenocarcinoma  AGS  (III 
and V), human colorectal adenocarcinoma HT-29 (III and IV) and murine macrophage 
RAW 264.7 (II) cells were all obtained from American Type Culture Collection. All cell 
types, except AGS, were grown in a medium consisting of Dulbecco’s Modified Eagle 
Medium (DMEM; 4.5 g/L glucose) supplemented with 10% fetal bovine serum (heat-
inactivated at 56 ºC for 30 min), 1% non-essential amino acids, 1% L-gutamine (200 mM), 
penicillin (100 UI/mL), and steptomycin (100 µg/mL). AGS cells were cultured in the 
same conditions, but the medium used was Roswell Park Memorial Institute (RPMI) 1640 
medium. The cells were maintained at 37 ºC in an incubator at an atmosphere of 5% CO2 
and  95% relative  humidity.  The  growth  medium was  replaced  three  times  a  week  during  
cell growth and differentiation.  
 
Prior to each experiment, the cells were harvested using a 0.25% (v/v) trypsin- 
Ethylenediaminetetraacetic acid-PBS solution and then seeded at the desired cell density. 
For the reactive oxygen species (ROS; I and II), nitric oxide (NO; I), tumor necrosis factor 
? (TNF-?; I and II) and viability assessment (I-V), 100 µl of cells were seeded at a density 
of 2×105 cells/mL  in  96-well  plates  in  DMEM  or  RPMI  1640  and  allowed  to  attach  
overnight. For the permeability studies (I-IV) and transmission electron microscopy (TEM) 
flat embedding using Caco-2 (I), 500 µl of cells in DMEM were seeded in 12-Transwell® 
cell culture inserts at a density of 1.5×105 cells/mL. The medium was changed three times a 
week and the cells for the permeation studies were used between 21 and 28 days after 
seeding. For the TEM flat embedding of RAW 264.7 macrophages (I), 3×104 cells in 
DMEM were seeded on top of a 13 mm glass round cover slip placed at the bottom of each 
12-well plate. For the confocal fluorescence microscopy (II, IV and V), 200 µl of cells in 
DMEM  at  a  density  of  1×107 cells/mL  were  seeded  in  a  8-well  chambered  No.  1  
borosilicate coverglass system plate (II) or 1 mL of cells in DMEM or RPMI at a density 
of 2×105 cells/mL  were  seeded  on  top  of  a  13  mm  glass  round  cover  slip  placed  at  the  
bottom of a 12-well plate (IV and V). For the flow cytometry measurements, 1 mL of cells 
in DMEM or RPMI at a density of 2×105 cells/mL was seeded in a 12-well plate (IV and 
V).  
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4.1.5 Dissolution media and other chemicals (I-V) 
The HBSS buffer was used as a medium for the drug release (III) and drug permeation (I-
IV)  studies,  and  ROS  (I and II),  NO  (I), TNF-? (I and II) and viability assays (I-V). 
Biological buffers [4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid] (HEPES) or [2-
(N-morpholino)ethanesulfonic  acid]  (MES)  at  10  mM  concentration  were  used  to  buffer  
the HBSS solutions to pH 7.4 and 5.5 (I-V) respectively. A mixture of 0.2 M HCl/ 0.2 M 
KCl was used as the pH 1.2 buffer. For the preparation of fasted state simulated intestinal 
fluid (FaSSIF) (I), NaOH pellets, glacial acetic acid and NaCl were used in purified water 
and the pH adjusted to 6.5.  
 
Solvents used in the manufacturing of the particles, HPLC analysis and drug 
loading/release quantification were EtOH (I-V),  phosphoric acid (I-V), acetonitrile (I, III 
and IV), DCM (I) and DMSO (III and IV). A solution of D-[14C]mannitol was also used to 
assess the Caco-2 monolayer integrity after the permeation studies (II).  
4.2 Analytical methods 
4.2.1 Physical methods (I-V) 
The DSC was carried out at  heating rates of 10 ºC/min under a N2 gas purge with a flow 
rate of 40 mL/min in order to detect crystalline fractions of the drug on the surface of the 
particles after loading (I and III). The porous properties of the particles were studied using 
N2 ad/desorption (I-V). The surface areas and pore characteristics of the particles were 
determined from the obtained data using the Brunauer-Emmet-Teller (BET) and Barret-
Joyner-Halenda (BJH) methods, respectively. Fourier transform infrared spectroscopy 
(FTIR) was used to evaluate chemical changes in the particle samples, as well as possible 
residual solvents after loading, coating or surface treatment (II, III and IV). The particle 
morphology was evaluated both from scanning electron microscopy (SEM) (I and III) and 
TEM images (I, II and IV). The cellular interactions were also evaluated using TEM 
images (I). The cellular association of fluorescently labeled particles was further evaluated 
using confocal fluorescence microscopy and flow cytometry (II, IV and V). Nanoparticle 
size distribution was also analyzed using a laser diffraction instrument (I, II, IV and V). 
The zeta (?)-potential of the nanoparticles (I, II, IV and V) was measured by a Zetasizer® 
instrument and calculated from the measured electrophoretic mobility using the 
Schmolukovski equation. 
4.2.2 Compound quantification (I, III-V) 
The concentration of the model compounds in the drug release, drug permeation, loading 
degree experiments and HFBII quantification were analyzed by HPLC and BCA. Detailed 
description of the HPLC experimental setup and conditions used can be found in the 
respective original publications (I, III-V). For the determination of [14C]mannitol, 100 µL 
samples were mixed with 4 mL of scintillation cocktail and the [14C]-activity was 
determined in each sample using a Liquid Scintillation Counter (II).  
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4.3 In vitro biocompatibility studies (I-V) 
The in vitro biocompatibility studies comprised ROS, NO, TNF-? and fluorescence-based 
and luminescence-based cell viability assays. The cell culturing media and seeding 
procedures are described in chapter 4.1.4. The assays were conducted in 96-well plates 
after  removing  the  culture  media  and  washing  the  wells  twice  with  HBSS  (pH  7.4).  All  
particles were dispersed in HBSS (pH 7.4) prior to the addition to the cell-containing wells 
and incubated with the cells for the desired exposure time. All assays were conducted at 
least in triplicate (n ? 3). 
4.4 Drug release experiments (III) 
The dissolution media used in the drug release experiments are described in chapter 4.1.5. 
The experiments were carried out using a paddle dissolution method at 100 rpm at 37 ºC as 
described in the European Pharmacopoeia. The volume of the media used was 500 mL at 
pH 1.2, 5.5 and 7.4, and all experiments were conducted under sink conditions. The IMC-
loaded THCPSi particles and the bulk IMC were weighed and placed in the dissolution 
glass vessels and the dissolution media added afterwards. During the drug release studies, 1 
mL aliquots were collected at the selected time intervals for quantification of the 
released/dissolved drug compound. The HPLC quantifications of the total amount of drugs 
loaded into the particles were carried out by weighing 1-3 mg of particles in 10 mL of pure 
DMSO, followed by adding 3 mL of EtOH. The mixtures were then vigorously stirred for 5 
h and the amount of released drug was quantified from the liquid fractions by HPLC. 
4.5 Permeability experiments (I-IV) 
The permeability of a fluorescein isothiocyanate (FITC)-labeled particles (II), griseofulvin 
(I) and IMC (III and IV) across differentiated Caco-2 cell monolayers (I-IV) in an apical-
to-basolateral direction was carried out using an apical pH of 5.5 and 7.4, and a basolateral 
pH of 7.4. Prior to all permeability experiments the cells were rinsed twice with HBSS (pH 
7.4) and then equilibrated in the transport buffers under the experimental conditions for 30 
min. The transepithelial electrical resistance (TEER) was measured prior to the 
experiments in order to confirm the integrity of the differentiated cell monolayer. 
Monolayers with TEER values above 250 ?cm2 were considered acceptable for the studies. 
The FITC-labeled THCPSi particles (II) in HBSS (pH 7.4) were introduced into the apical 
compartment and basolateral samples were collected at the selected time intervals, with the 
sample volume withdrawn replaced by fresh HBSS (pH 7.4). The samples were then 
analyzed for fluorescence and compared with the initial fluorescence values from the apical 
side. Griseofulvin was introduced into the apical compartment (I) either as a bulk powder 
or loaded into the TOPSi particles at pH values of 5.5 and 7.4. The samples were collected 
as described for the FITC-labeled THCPSi particles, but in this case the griseofulvin 
analysis was carried out by HPLC. Bulk IMC and the IMC-loaded into uncoated or HFBII-
coated THCPSi microparticles (III)  at  pH  values  of  5.5  and  7.4  was  also  analyzed  as  
described previously for griseofulvin. All permeability experiments were conducted at least 
in triplicate (n ? 3). 
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The differentiated monolayer integrity was controlled after each permeability experiment 
by two methods. First, the cells were washed once with HBSS at the experimental pH and 
the TEER values were measured (I-IV). In addition, the monolayer integrity was further 
assessed after the drug permeability tests with [14C]mannitol. The apical washing solution 
was removed and replaced by 500 µL of a solution with [14C]mannitol (30 µL stock 
solution in 5 mL HBSS) at the experimental pH conditions. After 60 min, the samples were 
taken from the apical and basolateral compartments for activity measurements. A diffusion 
rate of ? 0.5%/h was taken as an indicator of normal monolayer integrity (II).  
4.6 In vivo experiments (II and V) 
All animal experiments were approved by the National Committee for Animal 
Experimentation in Finland (State Provincial Office of Southern Finland, Hämeenlinna). 
The 18F-labeled THCPSi particles (II and V) were administered to male Wistar Han rats, 
aged 7-10 weeks, in 5% Solutol-1×HBSS (pH 7.4) either by intragastric gavage (II and V), 
subcutaneously on the back (II) or i.v. via the lateral tail vein (II).  The  control  animals  
received 18F-NaF in 5% Solutol-1×HBSS (pH 7.4). The animals were sacrificed at 2, 4 and 
6 h, or at 30 min, 1 and 4 h after administration for enteral and parental routes, 
respectively. 
 
Samples from blood, urine, mesenteric lymph node, liver lung, kidney, spleen, testis, brain, 
bone, and stomach were collected and measured for radioactivity. For intestinal 
biodistribution  of  particle  radioactivity,  the  lower  GI  tract  was  excised  and  samples  were  
taken from the duodenum, jejunum, ileum, cecum, and the ascending, transverse and 
descending  parts  of  the  intestine.  The  samples  were  weighed  and  their  radioactivity  was  
measured with a gamma counter. For the animals dosed with intragastric gavage, the lower 
gastrointestinal tract was imaged with digital autoradiography prior to sampling for 
radioactivity counting. The excised intestines were arranged on an imaging plate together 
with 18F standards, photographed for macroanatomical identification of the different 
intestinal parts and analyzed with imaging software.  
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5 Results and discussion 
5.1 Particle characterization (I-V) 
The PSi particles studied in this dissertation differ between them in several 
physicochemical properties. While the TOPSi particles are hydrophilic due to their oxide 
terminated bonds at the surface, THCPSi are hydrophobic due to the hydrogen atoms on 
the surface. Besides surface area, pore diameter and pore volume of both TOPSi and plain 
THCPSi micro- and nanoparticles, HFBII coated particles were also characterized. The 
results are presented in Table 5. 
Table 5 Characterization of TOPSi, plain THCPSi and HFBII-coated THCPSi particles. 
Particle Surface area 
(m2/g) 
Pore volume 
(cm3/g) 
Pore diameter 
(nm) 
?-potential 
(mV) 
TOPSi micro 202 0.63 9.2 ? 
TOPSi nano 177 0.63 15.7 –33.7 ± 4.4 
THCPSi micro 231  0.63  8.4  ? 
THCPSi nano 202 0.51 9.0 –34.1 ± 1.9 
THCPSi-HFBII micro 180  0.52  8.4  ? 
 
The microparticles studied, with size fractions ranging from 1-10 to 25-75 µm, and the 
nanoparticles, with sizes ranging from 97 to 188 nm, displayed a highly porous structure 
(Figure 3A), which contributed to their high surface area. The nanoparticles used in the 
experiments  displayed  a  very  uniform  spherical  shape,  with  a  narrow  size  distribution  
(Figure 3B and 3C). The high surface area of the PSi particles enables drug loading and 
confinement, which in turn increases drug dissolution rates (Salonen et al., 2005). The 
HFBII  coating  of  the  particles  carried  out  in  the  experiments  (III) decreased the surface 
area, which can be partially due to the increase in the sample mass by weight of the HFBII 
layer. As the pore volume is decreased, it may be possible that a small amount of HFBII 
may block the pores and thus reducing the available specific surface area and pore volume 
during the N2 sorption method.  
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Figure 3 SEM image of the porosity of PSi particles (A) and TEM images of TOPSi (B) and 
THCPSi (C) nanoparticles. The scale bars depicted are 100 nm (A), 1 ?m and 100 nm 
for the inset (B) and 0.5 ?m (C).Copyright © (2010, 2011) American Chemical Society 
and Elsevier. Reprinted with permission. 
The pore characteristics of PSi materials can be modulated through the control of generally 
used diluted HF electrolyte solutions, etching current and surface tension reducing agents. 
Usually, an increase in current density or anodization potential also leads to an increase in 
the pore diameter and straighter pores, and the increasing pore sizes generally decrease the 
interpore connections and pore branching (Zhang, 2001). The decreased surface area and 
increased average pore diameter of the particles used in our experiments are a result of the 
different etching current profiles used in the production of the nanoparticles. The current 
modulates the pore morphology enlarging the pore openings in the nanoparticles, leading to 
the increase in the average pore diameter and decrease in surface area. Due to the same 
reason, the pore volume of the nanoparticles remained almost invariable and rather similar 
to the pore volume of the microparticles (I). 
 
The control of the pore properties of PSi is an important parameter when biocompatibility 
is concerned. The porosity of the PSi based materials has been found to alter their 
degradation profile, as high-porosity mesoporous films exhibited substantial dissolution, 
and consequent biodegradability in vivo (Canham et al., 1999). Moreover, degradation of 
PSi particles, is faster under alkaline pH conditions, and it has been found to yield harmless 
products, such as Si(OH)4 which is excreted in the urine through the kidneys (Jugdaohsingh 
et al., 2002), and is well tolerated in vivo (Park et al., 2009). The PSi porosity degree is 
also a critical parameter that affects the crystalinization behavior of the drugs inside and 
outside of the pores as well as the subsequent drug release.  
 
The measured ?-potential of the studied nanoparticles showed a strongly negatively 
charged surface, which prevented aggregation and stabilized the particles in suspension. In 
addition, the HFBII coating maintained the negative charge of the particles (–25.8 ± 13.0), 
despite adsorbing onto the particles’ surface (V). The stability of the HFBII coating on the 
THCPSi particle surface was found to be higher at lower pH values (1.2) and displayed an 
abrupt decrease on protein desorption from the particles’ surface after incubation at pH 7.4 
and  37  ºC  (Figure  4).  The  mechanism  of  HFBII  adsorption  to  Si  surfaces  is  still  poorly  
understood. However, we have considered that the protein is most likely strongly adsorbed 
onto the surface of the PSi’s surface under the experimental conditions studied. The nature 
of the hydrophobin protein attraction was hypothesized to be of two types: (1) electrostatic 
A B C 
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patch charge attraction, which is due to the presence of an equal number of positively and 
negatively charged groups arranged in a mosaic pattern at each of the film surfaces, with 
opposing charge sites facing each other (Richmond, 1974; Basheva et  al., 2011); and (2) 
short–range hydrophobic interaction due to the presence of amino-acid residues with 
hydrophobic side chains on the water-facing part of the HFBII molecule (Meyer et al., 
2006; Hammer et al., 2010). Both these interactions represent a non-covalent binding and, 
moreover, it has also been reported that the HFBII adsorption to hydrophobic solids was 
found  to  be  weaker  than  that  of  HFBI  (Askolin et al., 2006). All together, the strong 
adsorption  of  HFBII  protein  onto  the  PSi  surfaces  seems  to  be  the  most  plausible  
explanation. 
 
 
Figure 4 Stability of the HFBII-coating on the THCPSi particle surface over time at pH values 
of 1.2, 5.5 and 7.4 after incubation at 37 ºC. Error bars represent SD (n ? 3). 
Copyright © (2011) Elsevier. Reprinted with permission. 
The THCPSi microparticles, when observed under SEM, displayed a pronounced surface 
roughness, whereas the HFBII coating induced smoothness in the particles’ surface (Figure 
5).  
 
Figure 5 SEM micrographs of uncoated (A, C and E) and HFBII-coated (B, D and F) THCPSi 
microparticles. The scale bars depicted are 5 µm (A and B) and 500 nm (C, D, E and 
F). Copyright © (2011) Elsevier. Reprinted with permission. 
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5.2 In vitro biocompatibility assessment (I-V) 
Engineered nanostructures have shown great promise in their ability to overcome many of 
the hurdles for delivering compounds to their desired sites of action. However, there is a 
great concern about the possible harmful effects that these structures may elicit when they 
interact with biological systems.  
 
The several tiers of oxidative response elicited by different concentrations, sizes and 
particle types were studied at different incubation times (I-V).The first set of experiments 
focused on the size and particle type in eliciting the first tier response of oxidative stress, in 
the form of ROS. The ROS assessment of both TOPSi (I) and THCPSi (II) showed that no 
significant increase was obtained in most of the concentrations and sizes studied in both 
particle types (I and II). Subsequently, inflammatory response was measured in terms of 
TNF-? production, which can be regarded as a second tier response of oxidative stress. 
TNF-? is a polypeptide cytokine produced by macrophages that stimulates acute phase 
reaction, which means that it can be used as an inflammatory response marker (Choi et al., 
2009). Together with NO induction, TNF-? has already been studied as a part of 
nanoparticle toxicity assessments in RAW 264.7 macrophages (Scheel et al., 2009). 
However, commercially available enzyme-linked immunosorbent assay (ELISA) for 
cytokine assessment can lead to differential cytokine binding to micro- and nanoparticles, 
which might contribute to the underestimation of inflammatory response results (Kocbach 
et al., 2008). Therefore, after assessing and correcting the values obtained by the ELISA in 
RAW 264.7 macrophage cells (I and II),  no  clear  concentration  dependence  in  the  cells  
was observed for the particles studied. Nevertheless, all microparticles, with size fractions 
of 1-10 and 10-25 µm, triggered a more pronounced inflammatory reaction than most of 
the nanoparticles, with the exception of the THCPSi particle sizes of 97 nm (II).  
 
Although still frequently used in viability determinations of Si particles, it has been shown 
that the PSi particles react with common colorimetric viability assays such as the MTT 
(Laaksonen et al., 2007) or LDH, which leads to overestimation of the cellular viability. 
Other reports have also suggested some limitations of most common cellular viability 
assays when nanomaterials are concerned (Monteiro-Riviere et  al., 2009). To investigate 
the toxic response of the PSi materials, the particles were incubated with several cell lines 
for 6, 12 or 24 h and cell viability was assessed by two different methods: (1) a luminescent 
method  (I-V) based on the quantification of the metabolically active (in terms of ATP 
content) cells (AshaRani et al., 2009; Santos et al., 2010); and (2) a fluorescent method (I) 
based on the detection of a conserved and constitutive protease activity associated with 
intact viable cells. The plain PSi micro- and nanoparticles.and their HFBII-coated 
counterparts were also evaluated in terms of their cytotoxicity at different concentrations. 
All uncoated particle types showed a size and concentration-dependent toxicity, with 
microparticles particles eliciting the greatest cytotoxic response (Figure 6). 
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Figure 6 Cell viability of Caco-2 cells incubated with THCPSi (A) and TOPSi (B) particles at 
24 h assessed by a luminescence-based assay. Error bars represent SD (n ? 3). 
Statistical analysis was made by ANOVA followed by a Dunnet’s multiple comparison 
test. All data sets were compared with a negative cytotoxicity control of HBSS.The 
level of significance was set at probability of *p < 0.05, **p < 0.01 and ***p < 0.001. 
Copyright © (2010, 2011) American Chemical Society and Elsevier. Reprinted with 
permission. 
The HFBII coating also changed the hydrophilicity of the THCPSi surfaces, turning them 
from hydrophobic to hydrophilic (III-V). This subsequent shift in hydrophobicity 
improved the particles’ biocompatibility, as already reported for other types of surfaces 
(Hezi-Yamit et al., 2009).The HFBII coating significantly increased the cell viability 
compared to uncoated particles both in micro- and nanoparticles (Figure 7). Microparticles 
were  found  to  elicit  the  greatest  cytotoxic  response  and  the  HFBII  coating  significantly  
improved the cell viability at concentrations of 50 and 15 ?g/mL (Figure 7A), whereas in 
the case of nanoparticles the improvement in viability was significant at concentrations of 
500 and 250 ?g/mL (Figure 7B)  
 
Figure 7 Cell viability of Caco-2 cells incubated with HFBII-coated THCPSi micro- (A) and 
nanoparticles (B) assessed by a luminescence-based assay. Error bars represent SD (n 
? 3). Statistical analysis was made by the Student’s t-test. The cell viability of 
uncoated particles was compared with their coated counterparts. The level of 
significance was set at probability of p < 0.05 for *, p < 0.01 for **. Copyright © 
(2011) Elsevier (2011). Reprinted with permission.  
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5.3 Drug release experiments (III) 
Drug release studies were made in order to evaluate the efficacy of the drug loading and the 
effect of the HFBII-coating on the drug release from PSi. At pH 1.2 it was observed that 
the uncoated THCPSi particles released ~12% of the loaded IMC after 120 min, but the 
HFBII-coated particles did not release any drug in the same time interval (Figure 8A). 
However, at pH 5.5 the drug release profiles were similar, with both types of particles 
releasing more than 90% of the loaded IMC at 48 h (Figure 8B). At pH 7.4, the IMC 
release rate was even faster, with more than 90% of drug released after 90 min for both the 
uncoated and the coated particles (Figure 8C).  
 
 
 
Figure 8 Drug release profiles of IMC-loaded THCPSi (?) and IMC-loaded HFBII-coated 
THCPSi (?) microparticles in buffer solutions at pH values of 1.2 (A), 5.5 (B) and 7.4 
(C) at 37 ºC. Dissolution medium was 0.2 M HCl/KCl (pH 1.2), 10 mM MES (pH 5.5) 
and 10 mM HEPES (pH 7.4). Error bars represent ±SD (n ? 3). Copyright © (2011) 
Elsevier. Reprinted with permission. 
Although both the uncoated and coated THCPSi particles allowed a fast IMC release, only 
the coated particles seem to protect the drug release at low pH-values, which makes the 
HFBII-coated THCPSi particles a promising pH-responsive carrier for oral drug delivery. 
As the pH is increased, a gradually faster IMC release is observed, which is rather 
advantageous due to the differences in the pH conditions along the GI tract. These results 
show that  despite  the  HFBII-coating,  which  rendered  the  particles  hydrophilic,  there  was  
no significant hindering of the IMC release at pH values of 5.5 and 7.4 (similarly to the 
uncoated THCPSi particles). However, at pH 1.2 there was no IMC release from the pores 
of the HFBII-coated particles unlike the uncoated ones. This feature is significant for the 
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protection of the drug against the harsh conditions of the stomach, avoiding possible 
degradation of the drug and even precipitation, which may hinder an efficient absorption of 
the drug in the intestine and reducing the drug’s pharmacological activity. 
5.4 Compound permeation (I-V) 
Caco-2 are human colon epithelial cancer cells that have been widely used as a model of 
human intestinal absorption of drugs and other compounds (Yee, 1997; van Breemen and 
Li, 2005). The permeation of compounds across the Caco-2 cell monolayer has also been 
shown to correlate with the fractional oral absorption data in humans (Artursson and 
Karlsson, 1991). In addition, Caco-2 cells express transporter proteins, efflux proteins, and 
Phase II conjugation enzymes to model a variety of transcellular pathways as well as 
metabolic  transformation  of  test  substances  (van  Breemen and  Li,  2005).  To  validate  the  
efficacy of the TOPSi nanoparticulate delivery system, the permeation properties of the 
nanoparticles loaded with griseofulvin (an antifungal drug) with a size of approximately 
170 nm were assessed (I). The results show a significant increase in drug permeation 
across the Caco-2 monolayers compared with the bulk drug at both pH 5.5 and 7.4 (Figure 
9A and 9B). This is probably due to the enhanced drug solubility obtained as a result of its 
loading into the TOPSi nanoparticles and consequent attainment of high local 
concentrations, and even drug supersaturation, which can increase the net drug absorption 
and respective permeation (Kaukonen et al., 2007; Brouwers et al., 2009).  
 
 
 
Figure 9 Permeation of bulk griseofulvin (?) and griseofulvin loaded TOPSi nanoparticles of 
170 nm (?) across a differentiated Caco-2 cell monolayer at apical pH of 5.5 (A) and 
7.4 (B). The basolateral solution was kept at pH 7.4 in all experiments. Error bars 
represent SD (n?3). Copyright © (2011) Elsevier. Reprinted with permission. 
As HFBII is a protein known to be extremely surface active, the question whether the 
HFBII-coating of the micro- and nanoparticles interfered with the drug permeation was 
raised. The permeation of IMC across a differentiated Caco-2 cell monolayer from the 
loaded THCPSi microparticles showed a significant increase when compared with bulk 
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IMC at pH values of 5.5 (Figure 10A) and 7.4 (Figure 10B). About 7% of the IMC 
permeated across the Caco-2 monolayer after 240 min when loaded into the THCPSi 
microparticles, whereas only 2% of the bulk IMC permeated in the same time interval at 
pH 5.5 (Figure 10A). At pH 7.4, the coated and uncoated IMC-loaded THCPSi 
microparticles showed no significant differences in the permeation profiles, with about 
30% of IMC permeating across the Caco-2 monolayer after 240 min (Figure 10B). The 
bulk  IMC  however,  only  permeated  20%  across  the  cell  monolayer  (Figure  10B).  These  
results suggest that the coated microparticles did not disrupt in any way the cell monolayer, 
nor  hampered  the  permeation  of  IMC from the  THCPSi  particles  (Figure  10A and  10B).  
The increase in the IMC permeation observed is probably due to the enhanced solubility of 
the drug as a result of the loading into the THCPSi microparticles (III). For the HFBII-
coated  THCPSi  nanoparticles,  the  results  showed  that  the  IMC  permeation  rate  from  the  
particles was found not to be significantly different from an IMC solution (Figure 10C). 
The IMC amount permeated across the differentiated Caco-2 monolayer was around 22% 
for the HFBII-coated THCPSi and IMC solution after 240 min. 
 
 
Figure 10 Permeation of bulk IMC (?), IMC solution (?), THCPSi-IMC, (?), THCPSi-IMC-
HFBII (?) and THCPSi-IMC-125I-HFBII (?) nanoparticles across a differentiated 
Caco-2 cell monolayer at apical pH of 5.5 (A) and 7.4 (B and C). The basolateral 
solution was kept at pH 7.4 in all experiments. Error bars represent SD (n?3). 
Copyright © (2011) Elsevier. Reprinted with permission. 
The increase in permeation from the TOPSi and THCPSi particles suggests that PSi can 
increase the solubility and, consequently, the drug permeation of poorly water-soluble 
drugs, regardless of particles’ surface chemistry. The HFBII coating on both THCPSi 
micro- and nanoparticles was also found not to hamper in any way the drug release or to 
disturb the Caco-2 cell monolayer. 
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5.5 Cellular interaction (I-IV) 
TOPSi microparticles, despite being in contact with the polarized Caco-2 cell monolayer 
for 24 h, did not attach or were internalized into the monolayer (Figure 11A and 11B). 
However, they seemed to remain in the close vicinity of the microvilli, which can be 
regarded as an advantageous property, as they can function as drug depots at the cell 
surface. This is the first reported evidence of such phenomenon. The TOPSi microparticles 
(1–10 ?m) in contact with the RAW 264.7 macrophages were readily phagocytized at 50 
?g/mL (Figure 11C), which lead in some cases to the disruption of the nuclear membrane. 
The particles seemed to be sequestered inside the lysosomal compartment for the duration 
of the assay, without any evidence of degradation (Figure 11D).  
 
 
Figure 11 TEM pictures (A, B, C and D) of flat embedded ultrathin sections of TOPSi 
microparticles (1-10 ?m, 50 ?g/mL) interactions with Caco-2 (A and B) and RAW 
264.7 macrophages(C and D) (scale bars are 2 ?m for A and C, 1 ?m for B and 500 
nm for D). Confocal microscopy images (E) of a RAW 264.7 macrophage stained in 
orang, interacting with FITC-THCPSi nanoparticles labeled green (scale bar 5 ?m). 
Copyright © (2010, 2011) American Chemical Society and Elsevier. Reprinted with 
permission. 
It was also observed that the majority of the THCPSi nanoparticles remained attached to 
the cell surface (Figure 11E). Positively charged particles were found to be internalized in a 
much greater extent than negatively charged particles (Gratton et al., 2008). Therefore, we 
postulate that the negative ?-potential of THCPSi particles together with their hydrophobic 
nature favors a strong particle-membrane interaction (Tavares et al., 2009), but extensive 
internalization is prevented (Gratton et al., 2008). The strong membrane interaction due to 
the THCPSi hydrophobic nature could cause toxicity (Tavares et al., 2009), an effect 
attenuated with the HFBII coating of these particles (III-V). Nonetheless, the HFBII-
coating of the PSi, despite maintaining the negative surface charge, was found to modulate 
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the adsorption of different types of proteins to the particles (Sarparanta et al., 2011), 
leading to a change in the composition of the corona (Walczyk et al., 2010), which in turn 
is implied in modulating cellular responses and biocompatibility (Kunzler et al., 2007; 
Myllymaa et al., 2010). Another important feature of the HFBII proteins is their ability to 
prevent other protein’s adhesion onto coated surfaces (Wang et al., 2010), which could be 
further explored for increased biocompatibility and particle i.v. applications. 
5.6 Biodistribution in rats (II and V)   
The suitability of THCPSi nanocarriers for drug delivery applications needs to be validated 
by biodistribution studies in vivo in order to establish a proof of principle for human 
applications. The FITC-label is quenched in acidic environments such as the stomach and 
is, therefore, unsuitable for labeling particles intended for oral administration. Instead, 
radiolabeled 18F-THCPSi nanoparticles were administered to male Wistar rats using three 
different routes: oral administration by intragastric gavage, subcutaneous and intravenous 
injections. The [18F]fluoride ion is a known bone-seeking radiotracer, showing high and 
rapid bone uptake in rats (Charkes et al., 1979; Schou et al., 2004). The control animals 
received 18F-NaF in the vehicle to establish the biodistribution pattern of free [18F]fluoride. 
The 18F accumulation in bone is commonly regarded as an indicator of the level of 
defluorination of the tracer in vivo (Charkes et al., 1979). Therefore, the administration to 
control  animals  of  [18F]F- as sodium fluoride to differentiate the biodistribution of 18F-
labeled nanoparticles from detached free 18F label was a crucial point to address. The 
results showed that the nanoparticles did not cross the intestinal wall, as seen by the 
negligible amount of radioactivity detected in the systemic circulation or organs outside the 
GI tract (Figure 12 A and 12B). 
 
 
Figure 12 Biodistribution of 18F-labeled THCPSi nanoparticles after oral administration (A) and 
their radioactivity distribution in the lower GI tract (B), as quantified by 
autoradiography (n= 3–4 at each time point; mean ± SD). Copyright © (2010) 
American Chemical Society. Reprinted with permission.  
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The observed appearance of radioactivity in bone and urine (< 0.6 ID%/g) at later time 
points was speculated to be due to minor detachment of the 18F-label, which can be caused 
by the in vivo defluorination or disintegration of the particles themselves. After i.v. 
administration into the lateral tail vein, the particles were found in the liver and spleen 
indicating that they are rapidly removed from the circulation. The THCPSi nanoparticles 
that were administered subcutaneously under the loose skin at the back of the animal 
resided in the subcutaneous space for up to 4 h post injection. The biodistribution data for 
subcutaneous administration showed only minimal leakage of dissociated 18F-label into the 
circulation and subsequent accumulation in bone and urine. As expected, significantly 
higher 18F bone uptake was seen in control animals in all administration routes. In addition, 
free 18F was rapidly extracted into urine in large amounts after i.v. and subcutaneous 
injections,  whereas  in  particle-dosed  animals  less  than  1  ID%/g  was  excreted  via  the  
kidneys (Figure 12A). In control animals dosed orally, slightly slower kinetics of bone 
uptake were observed compared to the parenteral routes. 
 
The HFBII coating was also found to endow the THCPSi nanoparticles of gastroretentive 
properties.  Upon  entry  of  THCPSi-18F-HFBII nanoparticles from the stomach into the 
intestines, it was observed that the particles were experiencing a delay compared with the 
uncoated ones. The HFBII-coated nanoparticles were found to be retained in the stomach 
up to three hours after administration, whereas the uncoated THCPSi were released in two 
hours in the same conditions (Figure 13). Interestingly, the amount of THCPSi-18F-HFBII 
nanoparticles retained in the stomach seems to peak at 2-3 hours after administration, 
suggesting that the nanoparticles are not immediately attached to the gastric mucosa, and 
are leached out as loose particles when the stomach is emptied. 
 
 
Figure 13 Gastric clearance of THCPSi-18F-HFBII nanoparticles versus uncoated THCPSi-
18Fnanoparticles. Values denote mean ± SD (n = 3). The level of significance was set 
at probability of p < 0.05 for *. 
THCPSi-18F-HFBII THCPSi-18F 
 40 
 
6 Conclusions and future perspectives 
The studies in this thesis ascertain the biocompatibility of PSi materials, regarding their 
inflammatory response, oxidative aggression and cell toxicity. The studies highlight 
different surface treated PSi micro- and nanoparticles and their ability to improve drug 
dissolution and drug permeation across biological barriers. By increasing the particle 
dissolution it is possible to achieve a higher drug concentration at the target site, therefore 
increasing the chances of a successful therapeutic outcome. Furthermore, the concentration 
and size dependent toxicity of these particulate systems was systematically established. 
Significant differences were found regarding several biocompatibility parameters between 
micro- and nanoparticles, which can impact the biomedical applications of these systems. 
PSi microparticles were shown to be more toxic than their nanoparticle counterparts. The 
nanoparticles were also found not to permeate across the gastrointestinal wall, but allowed 
the loaded drug to be released and become freely available for absorption. Once the 
particles were dissolved, they yielded harmless degradation products in the form of silicic 
acid. The relevance of this kind of technology is many folds, especially in solid state 
pharmaceutical and nanomedicine applications. The biodistribution of thermally 
hydrocarbonized PSi nanoparticles was also examined, showing that the intravenously 
injected nanoparticles were quickly sequestered to the liver and spleen. The employment of 
a self-assembling protein to coat the particles was also object of investigation. The coating 
was found to reverse the hydrophobicity and improved the biocompatibility of hydrophobic 
particles with several cell lines. The hydrophobin class II coating onto the particles was 
also found not to disturb the drug release from the pores of the particles and to improve cell 
association. The increased cell association is hypothesized to allow the release of the drug 
in closer vicinity to the cells, and therefore, increasing the drug’s bioavailability. These 
coated nanoparticles were also found to possess gastro-retentive properties, allowing them 
to be employed with drugs with a narrow window of absorption. The gastro-retentive 
properties and the particle’s coating stability were validated both in vitro and in vivo using 
radiolabeled particles. The results showed that the coating was stable for several hours and 
that the particles lost their coating and gastro-retention after being retained in the stomach 
for more than three hours. PSi particles emerge hence as a very promising platform for 
controlled drug delivery and imaging applications.  
 
Further functionalization, endowing the particles with shielding for opsonization and active 
targeting, is envisioned in the future. Multiple cargo loading, with small molecule drugs 
and DNA material for genetic therapy are also conjectured, allowing the PSi nanoparticles 
to fulfill their role as promising nanomedicine carriers. 
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